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Abstract
Toll-like receptor (TLR)-8 agonists typified by the 2-alkylthiazolo[4,5-c]quinolin-4-amine
(CL075) chemotype are uniquely potent in activating adaptive immune responses by inducing
robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds
could be promising candidate vaccine adjuvants, especially for neonatal vaccines.
Alkylthiazoloquinolines with methyl, ethyl, propyl and butyl groups at C2 displayed comparable
TLR8-agonistic potencies; activity diminished precipitously in the C2-pentyl compound, and
higher homologues were inactive. The C2-butyl compound was unique in possessing substantial
TLR7-agonistic activity. Analogues with branched alkyl groups at C2 displayed poor tolerance of
terminal steric bulk. Virtually all modifications at C8 led to abrogation of agonistic activity.
Alkylation on the C4-amine was not tolerated, whereas N-acyl analogues with short acyl groups
(other than acetyl) retained TLR8 agonistic activity, but were substantially less water-soluble.
Immunization in rabbits with a model subunit antigen adjuvanted with the lead C2-butyl
thiazoloquinoline showed enhancements of antigen-specific antibody titers.
Introduction
There can be no greater substantiation of Benjamin Franklin’s adage, ‘An ounce of
prevention is better than a cure’ than the resounding impact that vaccines have had in
preventing morbidity and mortality due to infectious diseases.1 Vaccines afford protection
by the induction of immune responses, both humoral and cellular, specifically directed
against the pathogen. Such adaptive immune responses are mobilized and amplified by
engagement of the innate immune system, a phylogenetically and teleologically ancient
system of host defense.2-4 Unlike adaptive immunity, the initial innate immune responses
rely on a limited number of germline-encoded pattern recognition receptors which recognize
specific molecular patterns present in molecules that are broadly shared by pathogens but are
sufficiently different so as to be distinguishable from host molecules.5,6
Innate immune afferent signals include those originating from Toll-like receptors (TLRs), as
well as RIG-I-like receptors7 and Nod-like receptors (NLRs).8,9 There are 10 functional
TLRs encoded in the human genome, which are trans-membrane proteins with an
extracellular domain having leucine-rich repeats (LRR) and a cytosolic domain called the
Toll/IL-1 receptor (TIR) domain.6 The ligands for these receptors are highly conserved
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molecules such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in
combination with TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and
TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9),
and profilin present on uropathogenic bacteria (TLR11).10 TLR1, -2, -4, -5, and -6 recognize
extracellular stimuli, while TLR3, -7, -8 and -9 function within the endolysosomal
compartment.6
The activation of TLRs by their cognate ligands leads to production of inflammatory
cytokines, and up-regulation of MHC molecules and co-stimulatory signals in antigen-
presenting cells as well as activating natural killer (NK) cells (innate immune response),
which leads to the priming and amplification of T-, and B-cell effector functions (adaptive
immune responses).11-14
In recognition that the initial innate immune responses serve to marshal, focus, and amplify
subsequent adaptive immune responses,15,16 there is considerable interest in utilizing TLR
agonists as vaccine adjuvants.17,18 In contradistinction to early vaccines which used killed
whole organisms,19-22 or attenuated live vaccines,23-25 modern vaccines increasingly rely on
subunit vaccines which have the distinct advantages of ease of production, quality control,
and safety; however, such subunit antigens which are largely soluble proteins are poorly
immunogenic, and require adjuvants to induce robust immune responses. Currently, the only
TLR agonist approved by the FDA as an adjuvant is 3-O-desacyl-4′-monophosphoryl lipid
A, (MPL), a TLR4 agonist derived from hydrolytic treatment of lipopolysaccharide isolated
from Salmonella minnesota Re595.26
We have recently begun exploring27,28 a variety of TLR agonists with a view to identifying
safe and potent vaccine adjuvants. The chemotypes that we have explored thus far include
agonists of TLR2,29-31 TLR7,32-36 nucleotide oligomerization domain 1 (Nod1),37 as well as
C-C chemokine receptor type 1 (CCR1).38 We now extend our investigations toward
delineating structure-activity relationships in small-molecule agonistic ligands of TLR8
(typified by the thiazolo[4,5-c]quinolines) for the following reasons:
First, the thiazoloquinolines are of interest because like the imidazoquinolines, these
compounds were identified in antiviral assays long before the discovery of the endosomal
TLR7 and TLR8 receptors,39-43 and other than the original landmark studies performed by
investigators at 3M Pharmaceuticals,44,45 structure-activity relationships in the
thiazoloquinoline chemotype remains poorly explored; qualitative assays for TNF-α and
IFN-α induction in human blood were performed in initial studies by 3M as surrogate
biomarkers of immunostimulation, and no data on TLR-7 and -8 specific agonistic activities
exist in the literature.
Second, TLR8 agonists, both single-stranded RNA as well as small molecule
imidazoquinoline ligands such as R-84846 and thiazoloquinolines such as 3M-002
(CL075)47,48 appear uniquely potent in activating costimulatory responses in neonatal
antigen-presenting cells (APCs), inducing robust production of the T helper 1 (Th1)-
polarizing cytokines TNF-α and IL-12, which are not observed upon stimulation by TLR-2,
-4, or -7 agonists. Such Th1-biasing compounds are of particular interest as candidate
vaccine adjuvants in the newborn.49 During the first few weeks of life, newborns rely almost
entirely on maternal IgG antibodies acquired by passive transplacental passage,50 and
remain susceptible to a wide range of pathogens until early infancy.51 Neonates and infants,
in whom vaccines could — and perhaps should — have the greatest impact do not mount
adequate adaptive immune responses, and therefore are most vulnerable; consequently, even
the most efficacious vaccines that confer excellent protection in adults may fail to elicit
strong immune responses in them.52,53 There is mounting evidence pointing to significant
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differences between adult and infant innate immune responses.54 The neonatal
immunophenotype is characterized by decreased production of both type I and type II
interferons, Interleukin (IL)-12, IL-18, IL-23 and other proinflammatory cytokines such as
Tumor Necrosis Factor-α (TNF-α), the preferential induction of memory B lymphocytes
rather than immunoglobulin-secreting plasma cells, as well as a pronounced T-helper type 2
(Th2) skewing of T-cell responses.51,52,55,56 TLR8 agonists induce the production of IL-12,
IL-18 and IFN-γ, and may therefore be of value in developing vaccines for the neonate.
Given the potential utility of TLR8 agonists as adjuvants for neonatal vaccines, it was of
interest to explore SAR in the thiazoloquinolines (typified by CL075, 8c in Scheme 1). Our
studies began with examining the optimal alkyl chain length at the C2 position. We found
that the C2-alkyl thiazoloquinolines exhibit mixed TLR8/7 agonistic activities in primary
reporter gene assays with the optimal chain length being butyl. We observed an
unexpectedly strict length dependence with only the C2-butyl, but none of the other
analogues, inducing IFN-α in human peripheral blood mononuclear cells (hPBMCs).
Examination of analogues with branched alkyl groups at C2 suggested poor tolerance of
terminal steric bulk. We noted, however that certain C2-branched analogues were
substantially more TLR8-selective than their corresponding straight-chain analogues.
Virtually all modifications at C8 led to abrogation of agonistic activity. Alkylation on the
C4-amine was not tolerated, whereas N-acyl analogues with short acyl groups (other than
acetyl) retained activity.
Results and Discussion
In our previous work on the TLR7-active imidazoquinolines, we had observed a distinct
relationship between C2-alkyl chain length and TLR7-agonistic potency,33 and we therefore
thought it logical to begin our SAR studies on the thiazoloquinolines by examining
analogues with C2-alkyl groups of varying chain lengths. These analogues (8a-8h, Scheme
1) were synthesized in parallel from the 3-aminoquinolin-4-ol precursor 4, using the strategy
described earlier.33,44
In primary screens using human TLR7 and TLR8-specific reporter gene assays, these
analogues exhibited mixed TLR8/TLR7 agonism; the EC50 values of 8c (CL075) were
found to be 1.32 μM and 5.48 μM, in TLR8 and TLR7 assays, respectively (Fig. 1, Table
1). As in our earlier SAR studies on the imidazoquinolines,33 we observed a clear
dependence of agonistic potency on the C2-alkyl chain length. The C2-methyl, -ethyl, and -
propyl analogues (8a-8c) displayed comparable potencies in the hTLR8 and hTLR7 reporter
gene assays (Fig. 1). Maximal TLR8-agonistic potency was observed in the butyl analogue
(8d). Increasing the chain length to pentyl (8e) led to attenuation of potency, and hgher
homologues (8f-8h) showed abrogation of activity (Fig. 1, Table 1).
The C2-butyl analogue 8d appeared to exhibit substantially higher TLR7-agonistic potency
than 8c (Figs. 1 and 3), suggesting that small variations at C2 could modulate TLR8 versus
TLR7 specificity. The introduction of an isopropyl group at C2 (8i) led to an approximately
ten-fold reduction in TLR8-agonistic potency (Table 1), while the attenuation of its activity
in TLR7-specific reporter gene assays was more modest (about two-fold). These results
warranted the syntheses of several additional analogues of both 8c (C2-n-propyl) and 8d
(C2-n-butyl) with branched alkyl groups at C2 (8j-8o, Scheme 1, Fig. 2). Additional methyl
substitutions at ω as well as ω-1 positions were well tolerated in 8c derivatives (8j and 8n,
respectively; Scheme 1, Fig. 2). On the other hand only the ω-1 methyl-substituted
compound 8o was active in the 8d series, whereas the 8l congener with a terminal methyl
substitution was entirely inactive. Both 8k and 8m bearing terminal trimethyl groups were
also inactive, suggesting poor tolerance of terminal steric bulk in these compounds.
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We also evaluated bioisosteric analogues 8p and 8q (Scheme 1) with terminal
trifluoromethyl groups. A decrease in potency at TLR8 was observed in the longer
homologue (8q). We noted that, in general, analogues with branched C2-alkyl groups of
optimal chain length and bulk (such as 8j, 8n, and 8o) are substantially more TLR8-selective
than their corresponding straight-chain analogues (Fig. 2).
However, in secondary cytokine induction screens using human PBMCs, the branched-chain
analogues behave differently in that they were neither as potent as their straight-chain parent
compounds (Fig. 3), nor did they show enhanced IL-12, IL-18, and IFN-γ production (data
not shown) as would be expected for TLR8-selective compounds.47,48 We do not yet
understand the basis of attenuated activity of the C2-branched analogues, and we are
currently exploring whether differential plasma protein binding behavior of these
compounds could be contributory.57
Previous reports on the thiazoloquinolines44,45,58 had been performed largely on the C7
position, and C8 and C4 analogues remain unexplored. We therefore first examined
substituents on the quinoline at the C8 position of 8c (CL075). Electrophilic substitution on
the quinoline ring selectively afforded the 8-nitro analogue 9 (Scheme 2), and the 8-bromo
analogue 14 (Scheme 4), both of which were inactive. The 8-amino (10) and 8-azido (11)
analogues were obtained from 9 (Scheme 2). Compound 10 showed attenuated activity
relative to 8c, and 11 was inactive. The triazole derivatives 12a-g were synthesized from 11
(Scheme 2) using conventional copper-catalyzed ‘click’ chemistry; of these analogues, the
triazolo analogue 12e displayed feeble, but selective TLR8 agonism (Table 1). Selective C8
N-alkylation and N-acylation of the 8-amino analogue 10 provided analogues 13a and 13b
(Scheme 3), both of which were inactive (Table 1).
Next, the C4-amine of 8c was alkylated or acylated, yielding analogues 15a-15l (Scheme 5).
The C4-N-alkylated compounds 15a and 15b were devoid of any agonistic activity, while
some, but not all of the C4-N-acylated derivatives with short acyl groups were found to be
active. Specifically, the formyl (15d), and butyryl (15f) analogues, but not the acetyl (15e)
compounds were active.
Although weaker in potency than the parent compound 8c, these C4-N-acyl derivatives
exhibited a pronounced specificity for TLR8 (Table 1). We observed an unusual
discontinuity in the activity profiles in this homologous series of compounds. The TLR8-
agonistic potency of the formyl analogue 15d was comparable to that of 8c. The acetyl
analogue 15e, however, was virtually inactive, but activity was partially restored in the
butyryl compound 15f (Fig. 4A), while higher homologues (15g and 15h) were inactive
(Table 1).
Cytokine induction profiles in hPBMCs mirrored these findings with a near-complete loss of
activity for the acetyl compound 15d (Fig. 5A).
Our provisional interpretation that a strict length requirement exists for the acyl substituents
on the C4-amine was borne out in compounds 15j-15l (azidoacetamide, azidopropionamide
and pentynamide analogues, respectively) which displayed weak, TLR8-selective agonistic
activity (Table 1). Aromatic amides at this position appear not to be tolerated, since the
benzamide analogue 15i was entirely inactive.
A series of carbamates (15m-15p), and sulfonamides (15r-sulfonamides (15r-15v) were also
synthesized (Scheme 5). The carbamate derivatives showed very weak activity in primary
reporter gene assays, while the sulfonamide analogues were completely inactive (Table 1).
Several other analogs including urea (15q; Scheme 5), phosphoramidate (15w; Scheme 5)
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and guanidine (17; Scheme 6) functional groups at C4 were also examined, but were found
to be inactive.
The peculiar SAR, with only the acetamide analogue (15e) showing loss of activity was
unexpected and, desiring to confirm this pattern, we also synthesized select amide analogues
of 8d (18a-18c, formamide, acetamide, and butyramide derivatives, respectively; Scheme 7).
As with the 8c derivatives, a virtually identical pattern was observed, with a selective loss of
activity for the acetamide analogue 18b (Fig. 4B, Fig. 5B, Table 1).
Our studies aimed at delinating structure-activity relationships in the thiazoloquinolines
have led to selecting 8d as a lead thiazoloquinoline. This compound distinguishes itself from
its closely-related congener, 8c (CL075) in possessing a more balanced TLR8/TLR7-
agonistic properties. Virtually all other analogues were either of lower potency, exhibited
very poor aqueous solubility (such as the amide analogues 15d and 18a), or despite apparent
greater TLR8 selectivity in primary screens, were either unremarkable in secondary screens
employing human PBMCs, or inferior in their cytokine induction profiles (8j, 8n, and 8o,
for instance). We therefore elected to directly evaluate the adjuvantic properties of 8d, and
benchmark it against 8c (CL075), noting that adjuvantic properties for the
thiazoloquinolines have not been previously reported in the literature. In light of the fact that
murine TLR8 is thought to be functionally inactive,59-61 we chose to examine the adjuvantic
activities of 8c, 8d directly in a rabbit model using bovine α-lactalbumin as a model subunit
vaccine antigen, which is a small (14 kDa), soluble protein which we have adopted as our
test-antigen in ongoing humoral and cellular immune response assays.35 We found that both
8c and 8d were adjuvantic in evoking high antigen-specific IgG titers (Fig. 6). Importantly,
no evidence of local or systemic toxicity was apparent in any of the cohorts. The data
suggests that 8d, with its dual TLR8/TLR7-agonistic properties, elicits adjuvanticity with
greater consistency and uniformity, as evidenced by narrower confidence intervals of
antibody titers (Fig. 6).
Conclusions
TLR8 agonists are thought to be uniquely potent in activating adaptive immune responses by
inducing robust production of T helper 1-polarizing cytokines, and may be promising
candidate vaccine adjuvants, especially for neonatal vaccines. Thiazoloquinoline analogues
with methyl, ethyl, propyl and butyl groups at C2 displayed comparable TLR8-agonistic
potencies; however, the C2-butyl compound 8d was unique in possessing substantial TLR7-
agonistic activity. Analogues with branched alkyl groups at C2 displayed poor tolerance of
terminal steric bulk. C4-N-acyl analogues with short acyl groups (other than acetyl) retained
TLR8 agonistic activity, but were substantially less water-soluble. Immunization in rabbits
with a model subunit antigen adjuvanted with the most potent TLR8 agonist showed
dramatic enhancements of antigen-specific antibody titers.
Experimental
Materials and Equipment
All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column chromatography was
carried out using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf
instrument unless otherwise mentioned, while thin-layer chromatography was carried out on
silica gel (200 μm) CCM pre-coated aluminum sheets. Purity for all final compounds was
confirmed to be greater than 98% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150
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mm, 5 μm analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN
gradients and either an Agilent ESI-TOF mass spectrometer (mass accuracy of 20 ppm) or
an Agilent 6520 ESI-QTOF mass spectrometer (mass accuracy of <10 ppm) operating in the
positive ion (or negative ion, as appropriate) acquisition mode.
Synthesis of compound 2: 2-(2-nitroethylideneamino)benzoic acid
Nitromethane (4.32 mL, 80 mmol) was added dropwise to a solution of NaOH (9.6 g, 250
mmol) in water (10 mL), at 0 °C. The mixture was then warmed to 40 °C and nitromethane
(4.32 mL, 80 mmol) was again added slowly at 40-45 °C. The temperature was maintained
until a clear solution was obtained. The reaction mixture was then heated to 55 °C for 2-5
minutes, cooled to 30 °C, poured onto crushed ice and acidified with conc. HCl (11 mL).
The resultant solution of methazoic acid was added immediately to a filtered solution of
anthranilic acid 1 (10 g, 73 mmol) and conc. HCl (3.3 mL) in water (75 mL). The reaction
mixture was allowed to stand at room temperature for 12 h. After filtration, the residue
obtained was washed with water, and dried to yield compound 2 (12.94 g, 85%). 1H NMR
(400 MHz, MeOD) δ 8.14 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 6.1 Hz, 1H), 7.68 – 7.59 (m, 2H),
7.22 (t, J = 7.4 Hz, 1H), 6.73 (d, J = 6.3 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 168.6,
141.2, 136.6, 134.3, 132.0, 123.2, 116.7, 114.5, 100.0. MS (ESI) calculated for C9H8N2O4,
m/z 208.05, found 209.06 (M+H)+.
Synthesis of compound 3: 3-nitroquinolin-4-ol
A solution of compound 2 (12.94 g, 62.2 mmol) in acetic anhydride (50 mL) was placed in a
2-neck flask fitted with a reflux condenser. It was stirred and heated to 105 °C until a clear
solution was obtained. Heating was then discontinued and potassium acetate (6.22 g, 63.5
mmol) was added. The mixture was then refluxed for 15 min with vigorous stirring, until a
solid started to precipitate. The reaction mixture was then slowly cooled to room
temperature. The residue was filtered, washed with glacial acetic acid until the washings
were colorless, then suspended in water, filtered, washed with water and dried at 110 °C to
get 3-nitroquinolin-4-ol 3 (4.68 g, 40%). 1H NMR (500 MHz, DMSO) δ 13.04 (s, 1H), 9.21
(s, 1H), 8.25 (dd, J = 8.1, 1.1 Hz, 1H), 7.83 – 7.77 (m, 1H), 7.74 – 7.70 (m, 1H), 7.52 (ddd, J
= 8.1, 7.1, 1.1 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 167.6, 142.5, 138.3, 133.2, 130.9,
128.1, 125.9, 125.8, 119.5. MS (ESI) calculated for C9H6N2O3, m/z 190.04, found 191.05
(M+H)+.
Synthesis of compound 4: 3-aminoquinolin-4-ol
To a solution of compound 3 (1.89 g, 9.93 mmol) in DMF (25 mL), was added 5% Pt on
carbon (20%, 0.38g). The reaction mixture was allowed to react in a Parr hydrogenation
apparatus at 60 psi H2 pressure for 3.5 h with vigorous shaking. The reaction mixture was
filtered through celite with several washes of methanol. The filtrate was concentrated by
evaporation to get 4-amino-3-nitroquinoline (1.5g, 94%). 1H NMR (500 MHz, MeOD) δ
8.90 (d, J = 8.1 Hz, 1H), 8.33 (d, J = 5.8 Hz, 1H), 8.30 – 8.23 (m, 2H), 7.97 (ddd, J = 8.1,
6.0, 1.9 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 146.9, 140.8, 138.9, 134.2, 131.2, 130.6,
128.7, 127.5. MS (ESI) calculated for C9H8N2O, m/z 160.06, found 161.07 (M+H)+.
Synthesis of compound 5a: N-(4-hydroxyquinolin-3-yl)acetamide
Compound 4 (200 mg, 1.25 mmol) was dissolved in a mixture of CH2Cl2 (20 mL) and DMF
(2 mL) and stirred at room temperature for 5 min. Acetyl chloride (133 μL, 1.875 mmol)
was added to the stirring reaction mixture at 0 °C and the solution was allowed to react for
1.5 h. Solvents were removed and the crude residue was purified using silica gel column
chromatography (10% MeOH/CH2Cl2) to obtain the compound 5a (106 mg, 42%). 1H NMR
(500 MHz, CDCl3) δ 9.20 (d, J = 5.5 Hz, 1H), 8.86 (s, 1H), 8.46 (s, 1H), 8.41 (dd, J = 8.3,
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1.0 Hz, 1H), 7.62 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 7.41 – 7.32 (m, 2H), 2.26 (s, 3H). 13C
NMR (126 MHz, CDCl3)δ 169.1, 137.9, 132.1, 126.6, 126.3, 123.6, 123.3, 122.9, 117.6,
24.6. MS (ESI) calculated for C11H10N2O2, m/z 202.07, found 203.08 (M+H)+.
Compounds 5b-5q were synthesized similarly as compound 5a.
5b: N-(4-hydroxyquinolin-3-yl)propionamide
(132 mg, 43%). 1H NMR (500 MHz, CDCl3) δ 9.29 (s, 1H), 8.71 (s, 1H), 8.42 (d, J = 7.7
Hz, 1H), 7.64 (t, J = 7.4 Hz, 1H), 7.49 (s, 1H), 7.38 (s, 1H), 2.56 (dd, J = 14.2, 7.0 Hz, 2H),
1.31 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 137.9, 132.2, 126.1, 126.1, 124.5,
124.1, 124.0, 123.9, 118.0, 30.6, 9.9. MS (ESI) calculated for C12H22N2O2, m/z 216.09,
found 217.10 (M+H)+.
5c: N-(4-hydroxyquinolin-3-yl)butyramide
1H NMR (500 MHz, MeOD) δ 9.02 (s, 1H), 8.28 (dd, J = 8.3, 1.3 Hz, 1H), 7.68 (ddd, J =
8.4, 7.0, 1.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.42 – 7.35 (m, 1H), 2.46 (t, J = 7.5 Hz, 2H),
1.74 (dd, J = 14.9, 7.4 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ
174.6, 172.2, 139.7, 133.1, 131.3, 126.2, 124.8, 124.7, 122.8, 119.4, 39.6, 20.3, 14.0. MS
(ESI) calculated for C13H14N2O2, m/z 230.11, found 231.11 (M+H)+.
5d: N-(4-hydroxyquinolin-3-yl)pentanamide
(155 mg, 52%). 1H NMR (500 MHz, CDCl3) δ 10.61 (s, 1H), 9.18 (s, 1H), 8.98 (s, 1H),
8.19 (d, J = 8.0 Hz, 1H), 7.72 – 7.62 (m, 2H), 7.37 – 7.30 (m, 1H), 2.44 (t, J = 7.4 Hz, 2H),
1.60 – 1.52 (m, 2H), 1.32 (dq, J = 14.7, 7.4 Hz, 2H), 0.89 (dd, J = 12.5, 5.1 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 171.6, 168.9, 138.0, 131.4, 129.1, 124.0, 123.0, 122.9, 121.4,
118.5, 27.4, 21.9, 13.8. MS (ESI) calculated for C14H16N2O2, m/z 244.12, found 245.13 (M
+H)+.
5e: N-(4-hydroxyquinolin-3-yl)hexanamide
(141 mg, 44%). 1H NMR (500 MHz, CDCl3) δ 9.65 (s, 1H), 8.44 (d, J = 8.2 Hz, 1H), 8.31
(d, J = 7.2 Hz, 1H), 7.88 (t, J = 7.4 Hz, 1H), 7.68 (t, J = 7.3 Hz, 1H), 2.82 (t, J = 6.5 Hz, 2H),
1.88 – 1.76 (m, 2H), 1.48 – 1.35 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 177.9, 137.1, 133.7, 128.0, 124.8, 122.0, 120.7, 120.1, 36.1, 31.3, 25.6, 22.5, 14.1.
MS (ESI) calculated for C15H18N2O2, m/z 258.14, found 259.15 (M+H)+.
5f: N-(4-hydroxyquinolin-3-yl)heptanamide
(105 mg, 31%). 1H NMR (500 MHz, CDCl3) δ 9.24 (d, J = 6.3 Hz, 1H), 8.88 (d, J = 1.6 Hz,
1H), 8.46 (s, 1H), 8.43 – 8.40 (m, 1H), 7.62 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.40 – 7.33 (m,
2H), 2.49 – 2.44 (m, 2H), 1.80 – 1.72 (m, 2H), 1.44 – 1.36 (m, 2H), 1.32 (td, J = 7.1, 3.5 Hz,
4H), 0.89 (dd, J = 9.7, 4.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.3, 170.7, 138.0,
132.0, 126.5, 126.3, 123.5, 123.3, 122.8, 117.6, 37.7, 31.7, 29.1, 25.8, 22.6, 14.2. MS (ESI)
calculated for C16H20N2O2, m/z 272.15, found 273.16 (M+H)+.
5g: N-(4-hydroxyquinolin-3-yl)octanamide
(263 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 9.25 (d, J = 6.4 Hz, 1H), 8.99 (s, 1H), 8.46
(s, 1H), 8.43 – 8.40 (m, 1H), 7.62 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.40 – 7.33 (m, 2H), 2.49 –
2.44 (m, 2H), 1.81 – 1.73 (m, 2H), 1.41 – 1.24 (m, 8H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 172.3, 170.8, 138.0, 132.0, 126.6, 126.3, 123.5, 123.3, 122.8, 117.6,
37.7, 31.9, 29.4, 29.2, 25.9, 22.8, 14.2. MS (ESI) calculated for C17H22N2O2, m/z 286.17,
found 287.18 (M+H)+.
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(231 mg, 59%). 1H NMR (500 MHz, CDCl3) δ 9.24 (s, 1H), 8.47 (s, 1H), 8.41 (dd, J = 8.2,
1.0 Hz, 1H), 7.63 – 7.58 (m, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.37 – 7.32 (m, 1H), 2.50 – 2.43
(m, 2H), 1.80 – 1.72 (m, 2H), 1.43 – 1.20 (m, 12H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 172.4, 170.8, 138.0, 132.0, 126.8, 126.2, 123.5, 123.3, 122.7, 117.7, 37.7,
32.0, 29.6, 29.5, 29.4, 29.4, 25.9, 22.8, 14.3. MS (ESI) calculated for C19H26N2O2, m/z
314.20, found 315.21 (M+H)+.
Synthesis of compound 6a: 2-methylthiazolo[4,5-c]quinoline
To a solution of compound 5a (100 mg, 0.49 mmol) in pyridine (10 mL), was added
phosphorous pentasulfide (109 mg, 0.49 mmol) and reaction mixture was refluxed for 2 h.
The resulting solution was cooled to room temperature and pyridine was removed under
reduced pressure. The residue was dissolved in water and pH was adjusted to 8 with
saturated sodium bicarbonate solution and extracted in ethyl acetate. The organic layer was
dried over sodium sulfate and concentrated to afford compound 6a (64 mg, 65%). 1H NMR
(500 MHz, CDCl3) δ 9.42 (s, 1H), 8.23 (d, J = 8.3 Hz, 1H), 7.94 (dd, J = 8.1, 0.9 Hz, 1H),
7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.62 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 2.94 (s, 3H). 13C
NMR (126 MHz, CDCl3) δ 167.5, 148.0, 145.6, 144.3, 141.1, 130.6, 128.8, 127.6, 125.0,
123.5, 20.3. MS (ESI) calculated for C11H8N2S, m/z 200.04, found 201.05 (M+H)+.
Compounds 6b-6q were synthesized similarly as compound 6a.
6b: 2-ethylthiazolo[4,5-c]quinoline
(90 mg, 70%). 1H NMR (500 MHz, CDCl3) δ 9.45 (s, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.99 –
7.94 (m, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.64 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.26
(q, J = 7.6 Hz, 2H), 1.54 (dd, J = 10.6, 4.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.2,
147.9, 145.8, 144.2, 140.6, 130.6, 128.8, 127.6, 125.0, 123.6, 28.0, 14.0. MS (ESI)
calculated for C12H10N2S, m/z 214.06, found 215.08 (M+H)+.
6c: 2-propylthiazolo[4,5-c]quinoline
(950 mg, 95%). 1H NMR (400 MHz, CDCl3) δ 9.45 (s, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.97
(dd, J = 8.1, 0.9 Hz, 1H), 7.74 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.69 – 7.59 (m, 1H), 3.26 –
3.11 (m, 2H), 2.04 – 1.92 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
172.8, 147.9, 145.8, 144.3, 140.7, 130.6, 128.8, 127.6, 125.0, 123.6, 36.4, 23.3, 13.8. MS
(ESI) calculated for C13H12N2S, m/z 228.07, found 229.08 (M+H)+.
6d: 2-butylthiazolo[4,5-c]quinoline
(108 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 9.44 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.96
(dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 5.4, 1.4 Hz, 1H), 7.63 (ddd, J = 8.1, 7.1, 1.1 Hz,
1H), 3.25 – 3.19 (m, 2H), 1.97 – 1.89 (m, 2H), 1.55 – 1.46 (m, 2H), 1.00 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 173.0, 147.9, 145.8, 144.2, 140.6, 130.6, 128.8, 128.8,
127.6, 125.0, 123.6, 34.2, 32.0, 22.4, 13.9. MS (ESI) calculated for C14H14N2S, m/z 242.09,
found 243.10 (M+H)+.
6e: 2-pentylthiazolo[4,5-c]quinoline
(104 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 9.45 (s, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.96
(dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.63 (ddd, J = 8.1, 7.1, 1.1 Hz,
1H), 3.24 – 3.17 (m, 2H), 1.95 (dt, J = 15.3, 7.7 Hz, 2H), 1.50 – 1.36 (m, 4H), 0.93 (t, J =
7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.1, 147.9, 145.8, 144.2, 140.7, 130.6, 128.8,
127.6, 125.0, 123.6, 34.4, 31.4, 29.6, 22.5, 14.1. MS (ESI) calculated for C15H16N2S, m/z
256.10, found 257.14 (M+H)+.
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(93 mg, 96%). 1H NMR (500 MHz, CDCl3) δ 9.45 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.97
(dd, J = 8.1, 0.9 Hz, 1H), 7.74 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.66 – 7.62 (m, 1H), 3.25 –
3.19 (m, 2H), 1.98 – 1.90 (m, 2H), 1.48 (dd, J = 10.5, 4.5 Hz, 2H), 1.36 (ddd, J = 16.3, 7.0,
4.9 Hz, 4H), 0.90 (dd, J = 9.4, 4.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.1, 147.9,
145.8, 144.3, 140.7, 130.6, 128.8, 127.6, 125.0, 123.6, 34.5, 31.6, 29.9, 28.9, 22.6, 14.2. MS
(ESI) calculated for C16H18N2S, m/z 270.12, found 271.14 (M+H)+.
6g: 2-heptylthiazolo[4,5-c]quinoline
(108 mg, 42%). 1H NMR (500 MHz, CDCl3) δ 9.44 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.96
(dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.65 – 7.60 (m, 1H), 3.22 –
3.17 (m, 2H), 1.94 (dt, J = 15.3, 7.6 Hz, 3H), 1.50 – 1.43 (m, 3H), 1.40 – 1.35 (m, 2H), 1.31
– 1.27 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.1, 147.9, 145.8,
144.2, 140.6, 130.6, 128.8, 127.6, 125.0, 123.6, 34.5, 31.8, 29.9, 29.2, 29.1, 22.7, 14.2. MS
(ESI) calculated for C17H20N2S, m/z 284.13, found 285.17 (M+H)+.
6h: 2-nonylthiazolo[4,5-c]quinoline
(157 mg, 52%). 1H NMR (500 MHz, CDCl3) δ 9.45 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.96
(d, J = 8.1 Hz, 1H), 7.73 (ddd, J = 8.4, 5.3, 1.4 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 3.23 – 3.18
(m, 2H), 1.94 (dt, J = 15.4, 7.7 Hz, 2H), 1.51 – 1.43 (m, 2H), 1.40 – 1.34 (m, 2H), 1.31 –
1.24 (m, 8H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.1, 147.9, 145.8,
144.2, 130.6, 128.8, 128.7, 127.6, 125.0, 123.6, 120.3, 34.5, 32.0, 29.9, 29.5, 29.4, 29.4,
29.2, 22.8, 14.2. MS (ESI) calculated for C19H24N2S, m/z 312.17, found 313.19 (M+H)+.
6i: 2-isopropylthiazolo[4,5-c]quinoline
164 mg, 83%. 1H NMR (500 MHz, CDCl3) δ 9.46 (s, 1H), 8.24 (d, J = 8.2 Hz, 1H), 8.01 –
7.96 (m, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.64 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.58 –
3.48 (m, 1H), 1.56 (d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 179.3, 147.8, 145.9,
144.2, 140.2, 130.6, 128.8, 127.6, 125.0, 123.7, 34.3, 23.1. MS (ESI) calculated for
C13H12N2S, m/z 228.10, found 229.08 (M+H)+.
6j: 2-isobutylthiazolo[4,5-c]quinoline
150 mg, 72%. 1H NMR (500 MHz, MeOD) δ 9.31 (s, 1H), 8.18 (d, J = 8.3 Hz, 1H), 8.11
(dd, J = 8.1, 0.9 Hz, 1H), 7.81 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.73 (ddd, J = 8.1, 7.1, 1.2 Hz,
1H), 2.30 (m, J = 13.7, 6.8 Hz, 1H), 1.08 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, MeOD)
δ 174.5, 148.7, 146.0, 144.7, 142.6, 130.5, 130.4, 129.3, 126.2, 124.7, 43.7, 31.1, 22.6. MS
(ESI) calculated for C14H14N2S, m/z 242.09, found 243.09 (M+H)+.
6l: 2-isopentylthiazolo[4,5-c]quinoline
165 mg 75%. 1H NMR (500 MHz, CDCl3) δ 9.44 (s, 1H), 8.26 – 8.22 (m, 1H), 7.98 – 7.95
(m, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.64 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.26 – 3.20
(m, 2H), 1.88 – 1.82 (m, 2H), 1.75 (dd, J = 13.3, 6.7 Hz, 1H), 1.01 (d, J = 6.6 Hz, 6H). 13C
NMR (126 MHz, CDCl3) δ 173.2, 147.9, 145.8, 144.3, 140.6, 130.6, 128.8, 127.6, 125.0,
123.6, 38.8, 32.5, 27.9, 22.5. MS (ESI) calculated for C15H16N2S, m/z 256.10.10, found
257.10 (M+H)+.
6o: (S)-2-(2-methylbutyl)thiazolo[4,5-c]quinoline
170 mg 77%. 1H NMR (500 MHz, CDCl3) δ 9.45 (s, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.96 (dd,
J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.63 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H),
3.21 (dd, J = 14.6, 6.2 Hz, 1H), 3.01 (dd, J = 14.6, 8.2 Hz, 1H), 2.12 – 2.02 (m, 1H), 1.58 –
Kokatla et al. Page 9













1.48 (m, 1H), 1.40 – 1.30 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 172.1, 147.9, 145.8, 144.2, 140.8, 130.6, 128.8, 127.6, 125.0,
123.6, 41.4, 36.3, 29.4, 19.2, 11.5. MS (ESI) calculated for C15H16N2S, m/z 256.10, found
257.10 (M+H)+.
6p: 2-(3,3,3-trifluoropropyl)thiazolo[4,5-c]quinoline
180 mg 74%. 1H NMR (500 MHz, CDCl3) δ 9.45 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.99 –
7.95 (m, 1H), 7.76 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.66 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.51 –
3.45 (m, 2H), 2.91 – 2.80 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 168.0, 147.7, 145.8,
144.4, 140.8, 130.7, 129.2, 127.8, 126.4 (q, 1JCF = 276.5 Hz), 125.0, 123.4, 33.0 (q, 2JCF =
29.8 Hz), 27.0 (q, 3JCF = 3.5 Hz). MS (ESI) calculated for C13H9F3N2S, m/z 282.04, found
283.04 (M+H)+.
6q: 2-(4,4,4-trifluorobutyl)thiazolo[4,5-c]quinoline
190 mg 75%. 1H NMR (500 MHz, CDCl3) δ 9.46 (s, 1H), 8.26 (d, J = 8.2 Hz, 1H), 8.00 –
7.95 (m, 1H), 7.76 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.66 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.32
(t, J = 7.2 Hz, 2H), 2.37 – 2.22 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 170.4, 147.9, 145.8,
144.4, 140.7, 130.7, 129.1, 127.8, 127.0 (q, 1JCF = 276.4 Hz), 125.0, 123.5, 33.9 (q, 2JCF =
28.9 Hz), 33.0, 21.1 (q, 3JCF = 3.0 Hz). MS (ESI) calculated for C14H11F3N2S, m/z 296.05,
found 297.06 (M+H)+.
Synthesis of compound 7a: 2-methylthiazolo[4,5-c]quinoline 5-oxide
To a solution of compound 6a (57 mg, 0.28 mmol) in CHCl3 (10 mL), was added m-
chloroperoxybenzoic acid (95 mg, 0.43 mmol) and the reaction mixture was stirred at room
temperature for 18 h. The solvent was then removed under reduced pressure and the crude
residue was purified using silica gel column chromatography (5% MeOH/CH2Cl2) to obtain
the compound 7a (57 mg, 94%). 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.89 (d, J = 8.9
Hz, 1H), 7.94 (dd, J = 7.9, 1.1 Hz, 1H), 7.81 – 7.72 (m, 2H), 2.93 (s, 3H). 13C NMR (126
MHz, CDCl3) δ 169.7, 147.2, 139.0, 131.5, 131.1, 129.9, 129.7, 125.6, 123.8, 121.6, 20.4.
MS (ESI) calculated for C11H8N2OS, m/z 216.04, found 217.05 (M+H)+.
Compounds 7b-7q were synthesized similarly as compound 7a.
7b: 2-ethylthiazolo[4,5-c]quinoline 5-oxide
(81 mg, 88%). 1H NMR (500 MHz, CDCl3) δ 9.15 (s, 1H), 8.90 (dd, J = 8.6, 0.8 Hz, 1H),
7.95 (dd, J = 8.0, 1.0 Hz, 1H), 7.82 – 7.72 (m, 2H), 3.23 (q, J = 7.6 Hz, 2H), 1.53 (d, J =
15.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.4, 147.1, 139.0, 131.6, 130.7, 129.9,
129.6, 125.6, 123.9, 121.6, 28.0, 13.9. MS (ESI) calculated for C12H10N2OS, m/z 230.05,
found 231.06 (M+H)+.
7c: 2-propylthiazolo[4,5-c]quinoline 5-oxide
(950 mg 88%). 1H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 8.90 (d, J = 8.7 Hz, 1H), 7.95
(dd, J = 7.9, 1.1 Hz, 1H), 7.82 – 7.71 (m, 2H), 3.17 (t, J = 7.6 Hz, 2H), 1.95 (dt, J = 14.9, 7.4
Hz, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 175.0, 147.1, 139.0,
131.6, 130.7, 129.9, 129.6, 123.9, 121.6, 36.4, 23.2, 13.8. MS (ESI) calculated for
C13H12N2OS, m/z 244.07, found 245.07 (M+H)+.
7d: 2-butylthiazolo[4,5-c]quinoline 5-oxide
(82 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.90 – 8.86 (m, 1H), 7.94 (dd, J
= 7.9, 1.1 Hz, 1H), 7.80 – 7.71 (m, 2H), 3.21 – 3.16 (m, 2H), 1.94 – 1.86 (m, 2H), 1.53 –
1.45 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 175.2, 147.1, 139.0,
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131.6, 130.6, 129.9, 129.6, 125.6, 123.9, 121.6, 34.2, 31.8, 22.4, 13.9. MS (ESI) calculated
for C14H14N2OS, m/z 258.08, found 259.09 (M+H)+.
7e: 2-pentylthiazolo[4,5-c]quinoline 5-oxide
(90 mg, 87%). 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.88 (d, J = 8.1 Hz, 1H), 7.94
(dd, J = 8.0, 1.2 Hz, 1H), 7.81 – 7.70 (m, 2H), 3.22 – 3.13 (m, 2H), 1.92 (dt, J = 15.4, 7.7
Hz, 2H), 1.48 – 1.36 (m, 4H), 0.92 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
175.3, 147.0, 138.9, 131.6, 130.7, 129.9, 129.6, 125.6, 123.9, 121.6, 34.5, 31.3, 29.5, 22.4,
14.0. MS (ESI) calculated for C15H16N2OS, m/z 272.10, found 273.11 (M+H)+.
7f: 2-hexylthiazolo[4,5-c]quinoline 5-oxide
(65 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 9.15 (s, 1H), 8.90 (d, J = 8.5 Hz, 1H), 7.96
(dd, J = 8.0, 1.0 Hz, 1H), 7.82 – 7.72 (m, 2H), 3.22 – 3.17 (m, 2H), 1.92 (dd, J = 15.3, 7.7
Hz, 2H), 1.51 – 1.44 (m, 2H), 1.40 – 1.30 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 175.3, 147.1, 139.0, 131.7, 130.8, 129.9, 129.6, 125.6, 123.9, 121.6, 34.5,
31.6, 29.8, 28.9, 22.6, 14.2. MS (ESI) calculated for C16H18N2OS, m/z 286.11, found
287.12 (M+H)+.
7g: 2-heptylthiazolo[4,5-c]quinoline 5-oxide
(81 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.88 (dd, J = 8.7, 0.8 Hz, 1H),
7.94 (dd, J = 7.9, 1.1 Hz, 1H), 7.80 – 7.71 (m, 2H), 3.21 – 3.15 (m, 2H), 1.91 (dt, J = 15.3,
7.6 Hz, 2H), 1.49 – 1.42 (m, 2H), 1.41 – 1.35 (m, 2H), 1.32 – 1.26 (m, 4H), 0.88 (t, J = 7.0
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 175.3, 147.0, 138.9, 131.6, 130.7, 129.9, 129.6,
125.6, 123.9, 121.6, 34.5, 31.7, 29.8, 29.2, 29.0, 22.7, 14.2. MS (ESI) calculated for
C17H20N2OS, m/z 300.13, found 301.14 (M+H)+.
7h: 2-nonylthiazolo[4,5-c]quinoline 5-oxide
(105 mg, 66%). 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.88 (d, J = 8.5 Hz, 1H), 7.93
(dd, J = 7.9, 1.1 Hz, 1H), 7.81 – 7.69 (m, 2H), 3.19 – 3.14 (m, 2H), 1.91 (dt, J = 15.3, 7.6
Hz, 2H), 1.45 (dt, J = 14.9, 7.0 Hz, 2H), 1.35 (dd, J = 14.2, 6.9 Hz, 2H), 1.29 – 1.21 (m, 8H),
0.86 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 175.3, 147.0, 138.9, 131.6, 130.7,
129.8, 129.6, 125.6, 123.9, 121.5, 34.5, 31.9, 29.8, 29.5, 29.3, 29.2, 22.8, 14.2. MS (ESI)
calculated for C19H24N2OS, m/z 328.16, found 329.17 (M+H)+.
7i: 2-isopropylthiazolo[4,5-c]quinoline 5-oxide
150 mg, 62%. 1H NMR (500 MHz, CDCl3) δ 9.15 (s, 1H), 8.90 (dd, J = 8.7, 1.0 Hz, 1H),
7.99 – 7.95 (m, 1H), 7.79 (ddd, J = 8.6, 7.0, 1.5 Hz, 1H), 7.77 – 7.72 (m, 1H), 3.54 – 3.45
(m, 1H), 1.54 (d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 181.5, 147.0, 138.9,
131.7, 130.3, 129.9, 129.6, 125.6, 124.0, 121.6, 34.4, 23.0. MS (ESI) calculated for
C13H12N2OS, m/z 244.07.10, found 245.07 (M+H)+.
7j: 2-isobutylthiazolo[4,5-c]quinoline 5-oxide
80 mg, 75%. 1H NMR (500 MHz, MeOD) δ 9.26 (s, 1H), 8.79 (dd, J = 8.6, 0.9 Hz, 1H),
8.25 – 8.21 (m, 1H), 7.95 (ddd, J = 8.7, 7.1, 1.5 Hz, 1H), 7.90 (ddd, J = 8.2, 7.1, 1.4 Hz, 1H),
3.14 (d, J = 7.2 Hz, 2H), 2.35 – 2.25 (m, 1H), 1.09 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz,
MeOD) δ 176.8, 147.8, 139.0, 135.3, 133.5, 131.7, 131.6, 127.2, 125.2, 121.5, 43.7, 31.0,
22.6. MS (ESI) calculated for C14H14N2OS, m/z 258.08.10, found 259.08 (M+H)+.
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80 mg, 75%. 1H NMR (500 MHz, MeOD) δ 9.31 (s, 1H), 8.79 (dd, J = 8.7, 0.9 Hz, 1H),
8.26 – 8.22 (m, 1H), 7.99 – 7.88 (m, 2H), 3.16 (s, 2H), 1.13 (s, 9H). 13C NMR (126 MHz,
MeOD) δ 174.7, 147.8, 138.8, 135.9, 133.8, 131.8, 131.7, 127.3, 125.1, 121.4, 48.3, 33.2,
29.9. MS (ESI) calculated for C14H16N2OS, m/z 272.10, found 273.10 (M+H)+.
7l: 2-isopentylthiazolo[4,5-c]quinoline 5-oxide
110 mg, 69%. 1H NMR (500 MHz, MeOD) δ 9.23 (s, 1H), 8.77 (dd, J = 8.6, 0.9 Hz, 1H),
8.21 – 8.18 (m, 1H), 7.93 (ddd, J = 8.7, 7.0, 1.5 Hz, 1H), 7.89 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H),
3.27 (dd, J = 8.4, 7.4 Hz, 2H), 1.88 – 1.82 (m, 2H), 1.78 – 1.69 (m, 1H), 1.02 (d, J = 6.6 Hz,
6H). 13C NMR (126 MHz, MeOD) δ 178.1, 147.7, 138.9, 135.1, 133.5, 131.6, 131.6, 127.1,
125.1, 121.5, 39.6, 33.1, 28.8, 22.6. MS (ESI) calculated for C15H16N2OS, m/z 272.10,
found 273.10 (M+H)+.
7m: 2-(3,3-dimethylbutyl)thiazolo[4,5-c]quinoline 5-oxide
80 mg, 76%. 1H NMR (500 MHz, MeOD) δ 9.22 (s, 1H), 8.77 (dd, J = 8.7, 0.9 Hz, 1H),
8.21 – 8.18 (m, 1H), 7.93 (ddd, J = 8.7, 7.1, 1.5 Hz, 1H), 7.89 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H),
3.27 – 3.22 (m, 2H), 1.89 – 1.84 (m, 2H), 1.04 (s, 9H). 13C NMR (126 MHz, MeOD) δ
178.7, 147.7, 138.9, 135.1, 133.4, 131.6, 131.6, 127.1, 125.1, 121.4, 44.7, 31.5, 30.9, 29.5.
MS (ESI) calculated for C16H18N2OS, m/z 286.11, found 287.11 (M+H)+.
7n: (S)-2-(sec-butyl)thiazolo[4,5-c]quinoline 5-oxide
117 mg, 78%. 1H NMR (500 MHz, MeOD) δ 9.23 (s, 1H), 8.77 (dd, J = 8.6, 1.0 Hz, 1H),
8.22 – 8.18 (m, 1H), 7.93 (ddd, J = 8.7, 7.1, 1.5 Hz, 1H), 7.88 (ddd, J = 8.2, 7.1, 1.4 Hz, 1H),
3.35 (dd, J = 13.9, 6.9 Hz, 1H), 2.04 – 1.94 (m, 1H), 1.92 – 1.82 (m, 1H), 1.52 (d, J = 6.9
Hz, 3H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 183.1, 147.7, 138.9,
134.7, 133.5, 131.6, 131.6, 127.1, 125.2, 121.5, 42.3, 31.6, 20.9, 12.0. MS (ESI) calculated
for C14H14N2OS, m/z 258.09, found 259.08 (M+H)+.
7o: (S)-2-(2-methylbutyl)thiazolo[4,5-c]quinoline 5-oxide
103 mg, 74%. 1H NMR (500 MHz, MeOD) δ 9.24 (s, 1H), 8.78 (dd, J = 8.7, 0.8 Hz, 1H),
8.23 – 8.19 (m, 1H), 7.94 (ddd, J = 8.7, 7.1, 1.5 Hz, 1H), 7.89 (dd, 1H), 3.26 (dd, J = 14.7,
6.2 Hz, 1H), 3.06 (dd, J = 14.7, 8.0 Hz, 1H), 2.14 – 2.03 (m, 1H), 1.60 – 1.50 (m, 1H), 1.44
– 1.30 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz,
MeOD) δ 177.0, 147.8, 139.0, 135.3, 133.5, 131.7, 131.6, 127.1, 125.1, 121.5, 41.8, 37.4,
30.2, 19.4, 11.6. MS (ESI) calculated for C15H16N2OS, m/z 272.10, found 273.10 (M+H)+.
7p: 2-(3,3,3-trifluoropropyl)thiazolo[4,5-c]quinoline 5-oxide
120 mg, 75%. 1H NMR (500 MHz, MeOD) δ 9.24 (s, 1H), 8.76 (dd, J = 8.8, 0.7 Hz, 1H),
8.17 (dd, 1H), 7.93 (ddd, J = 8.6, 7.0, 1.4 Hz, 1H), 7.88 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 3.54
(t, 2H), 2.99 – 2.87 (m, 2H).13C NMR (126 MHz, MeOD) δ 173.8, 147.6, 139.1, 135.2,
133.6, 131.8, 131.6, 128.1 (q, 1JCF = 275.6 Hz), 127.1, 125.0, 121.5, 33.2 (q, 2JCF = 29.7
Hz), 27.7 (q, 3JCF = 3.5 Hz). MS (ESI) calculated for C13H9F3N2OS, m/z 298.04, found
299.04 (M+H)+.
7q: 2-(4,4,4-trifluorobutyl)thiazolo[4,5-c]quinoline 5-oxide
128 mg, 81%. 1H NMR (500 MHz, MeOD) δ 9.26 (s, 1H), 8.80 – 8.74 (m, 1H), 8.22 – 8.18
(m, 1H), 7.94 (ddd, J = 8.6, 7.1, 1.5 Hz, 1H), 7.89 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 3.36 (t, J =
7.5 Hz, 2H), 2.48 – 2.34 (m, 2H), 2.27 – 2.17 (m, 2H). 13C NMR (126 MHz, MeOD) δ
176.0, 147.8, 139.0, 135.2, 133.6, 131.7, 131.6, 128.6 (q, 1JCF = 275.4 Hz), 127.1, 125.1,
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121.5, 33.6 (q, 2JCF = 29.0 Hz), 33.5, 22.6 (q, 3JCF = 3.2 Hz). MS (ESI) calculated for
C14H11F3N2OS, m/z 312.05, found 313.05 (M+H)+.
Synthesis of compound 8a: 2-methylthiazolo[4,5-c]quinolin-4-amine
Compound 7a (50 mg, 0.23 mmol) was dissolved in anhydrous CH2Cl2 (5 mL). Benzoyl
isocyanate (68 mg, 0.46 mmol) was added to the reaction mixture and refluxed for 30 min.
The solvent was then removed under vacuum and the residue was dissolved in anhydrous
methanol (5 mL). Excess of sodium methoxide was added and the reaction mixture was
refluxed for 2 h. After evaporating solvents under reduced pressure, the crude residue was
purified using silica gel column chromatography (7% MeOH/CH2Cl2) to obtain compound
8a as a white solid (41 mg, 82%). 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz,
1H), 7.72 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1,
7.1, 1.2 Hz, 1H), 5.61 (s, 2H), 2.89 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.9, 151.5,
144.8, 141.0, 138.1, 129.1, 126.8, 124.8, 123.2, 120.1, 20.1. MS (ESI) calculated for
C11H9N3S, m/z 215.05, found 216.06 (M+H)+.
Compounds 8b-8q were synthesized similarly as compound 8a.
8b: 2-ethylthiazolo[4,5-c]quinolin-4-amine
White solid (36 mg, 47%). 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.74 (dd, J = 8.0, 1.1 Hz, 1H), 7.56 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.1 Hz, 1H), 5.58 (s, 2H), 3.20 (q, J = 7.6 Hz, 2H), 1.51 (t, J = 7.6 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 172.6, 151.6, 144.8, 140.4, 138.0, 129.0, 126.8, 124.8, 123.2, 120.2, 27.8,
14.1. MS (ESI) calculated for C12H11N3S, m/z 229.07, found 230.08 (M+H)+.
8c: 2-propylthiazolo[4,5-c]quinolin-4-amine
White solid (450 mg, 90%). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.4 Hz, 1H), 7.73
(dd, J = 8.0, 1.3 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.34 – 7.27 (m, 1H), 5.67 (s,
2H), 3.13 (t, J = 7.6 Hz, 2H), 1.94 (dd, J = 15.0, 7.4 Hz, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 171.2, 151.7, 144.7, 140.5, 138.0, 129.0, 126.8, 124.8, 123.1,
120.2, 36.2, 23.4, 13.8. MS (ESI) calculated for C13H13N3S, m/z 243.08, found 244.09 (M
+H)+.
8d: 2-butylthiazolo[4,5-c]quinolin-4-amine
White solid (25 mg, 32%). 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.6 Hz, 1H),
7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.56 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.2 Hz, 1H), 5.56 (s, 2H), 3.20 – 3.13 (m, 2H), 1.90 (dt, J = 15.3, 7.6 Hz, 2H), 1.50 (dq, J =
14.7, 7.4 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.5, 151.6,
144.7, 140.5, 138.0, 129.0, 126.8, 124.8, 123.2, 120.2, 34.0, 32.0, 22.4, 13.9. MS (ESI)
calculated for C14H15N3S, m/z 257.10, found 258.11 (M+H)+.
8e: 2-pentylthiazolo[4,5-c]quinolin-4-amine
White solid (38 mg, 45%). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.1 Hz, 1H), 7.73 (dd,
J = 8.0, 1.1 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.34 – 7.29 (m, 1H), 5.59 (s, 2H),
3.18 – 3.12 (m, 2H), 1.96 – 1.86 (m, 2H), 1.50 – 1.35 (m, 4H), 0.94 (t, J = 7.1 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 171.5, 151.6, 144.7, 140.5, 138.0, 129.0, 126.8, 124.8, 123.2,
120.2, 34.3, 31.4, 29.7, 22.5, 14.1 MS (ESI) calculated for C15H17N3S, m/z 271.11, found
272.12 (M+H)+.
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White solid (25 mg, 44%). 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.1 Hz, 1H), 5.56 (s, 2H), 3.21 – 3.11 (m, 2H), 1.91 (dt, J = 15.3, 7.5 Hz, 2H), 1.46 (dt, J =
9.2, 7.0 Hz, 2H), 1.39 – 1.30 (m, 4H), 0.91 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3)
δ 171.6, 151.6, 144.7, 140.51, 138.0, 129.1, 126.8, 124.8, 123.2, 120.2, 34.3, 31.6, 30.0,
29.0, 22.6, 14.2. MS (ESI) calculated for C16H19N3S, m/z 285.13, found 286.14 (M+H)+.
8g: 2-heptylthiazolo[4,5-c]quinolin-4-amine
White solid (34 mg, 42%). 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.2 Hz, 1H), 5.56 (s, 2H), 3.20 – 3.08 (m, 2H), 1.91 (dt, J = 15.3, 7.6 Hz, 2H), 1.50 – 1.42
(m, 2H), 1.38 (ddd, J = 14.0, 8.2, 5.2 Hz, 2H), 1.30 (dt, J = 11.5, 3.9 Hz, 4H), 0.89 (t, J = 6.9
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.6, 151.6, 144.7, 140.5, 138.0, 129.0, 126.8,
124.8, 123.2, 120.2, 34.3, 31.8, 30.0, 29.2, 29.1, 22.8, 14.2. MS (ESI) calculated for
C17H21N3S, m/z 299.15, found 300.16 (M+H)+.
8h: 2-nonylthiazolo[4,5-c]quinolin-4-amine
(26 mg, 26%). 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.73 (dd, J =
8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H),
5.57 (s, 2H), 3.21 – 3.09 (m, 2H), 1.91 (dt, J = 15.3, 7.6 Hz, 2H), 1.46 (ddd, J = 14.9, 8.7,
6.5 Hz, 2H), 1.36 (dd, J = 13.7, 6.7 Hz, 2H), 1.28 (s, 8H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 171.6, 151.6, 144.7, 140.5, 138.0, 129.0, 126.8, 124.8, 123.2, 120.2,
34.3, 32.0, 30.0, 29.6, 29.4, 29.4, 29.2, 22.8, 14.3. MS (ESI) calculated for C19H25N3S, m/z
327.18, found 328.19 (M+H)+.
8i: 2-isopropylthiazolo[4,5-c]quinolin-4-amine
White solid (40 mg, 67%). 1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.75 – 7.71 (m, 1H), 7.55 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H),
5.66 (s, 2H), 3.51 – 3.41 (m, 1H), 1.52 (d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ
177.7, 151.8, 144.7, 140.0, 137.9, 129.0, 126.8, 124.8, 123.1, 120.3, 34.2, 23.2. MS (ESI)
calculated for C13H13N3S, m/z 243.09.10, found 244.09 (M+H)+.
8j: 2-isobutylthiazolo[4,5-c]quinolin-4-amine
White solid (38 mg, 77%).1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.1 Hz, 1H), 5.63 (s, 2H), 3.02 (d, J = 7.2 Hz, 2H), 2.30 – 2.20 (m, 1H), 1.06 (d, J = 6.6 Hz,
6H). 13C NMR (126 MHz, CDCl3) δ 170.3, 151.7, 144.8, 140.6, 138.1, 129.1, 126.8, 124.9,
123.1, 120.2, 43.1, 30.0, 22.5. MS (ESI) calculated for C14H15N3S, m/z 257.10, found
258.10 (M+H)+.
8k: 2-neopentylthiazolo[4,5-c]quinolin-4-amine
White solid (45 mg, 76%).1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.74 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 5.5, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.1 Hz, 1H), 5.60 (s, 2H), 3.04 (s, 2H), 1.10 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 168.1,
151.7, 144.8, 140.7, 138.2, 129.1, 126.8, 124.9, 123.2, 120.1, 47.8, 32.3, 29.7. MS (ESI)
calculated for C14H17N3S, m/z 271.11, found 272.11 (M+H)+.
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White solid (40 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.1 Hz, 1H), 5.61 (s, 2H), 3.20 – 3.13 (m, 2H), 1.84 – 1.78 (m, 2H), 1.77 – 1.69 (m, 1H),
1.00 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 171.7, 151.6, 144.7, 140.5, 138.0,
129.0, 126.8, 124.8, 123.2, 120.2, 38.9, 32.3, 27.9, 22.5. MS (ESI) calculated for
C15H16N2OS, m/z 271.11, found 272.11 (M+H)+.
8m: 2-(3,3-dimethylbutyl)thiazolo[4,5-c]quinolin-4-amine
White solid (45 mg, 65%). 1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.74 – 7.70 (m, 1H), 7.55 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H),
5.64 (s, 2H), 3.17 – 3.09 (m, 2H), 1.86 – 1.79 (m, 2H), 1.02 (s, 9H). 13C NMR (126 MHz,
CDCl3) δ 172.2, 151.6, 144.7, 140.4, 138.0, 129.0, 126.8, 124.8, 123.1, 121.0, 44.1, 30.8,
30.1, 29.3. MS (ESI) calculated for C16H19N3S, m/z 285.13, found 286.14 (M+H)+.
8n: (S)-2-(sec-butyl)thiazolo[4,5-c]quinolin-4-amine
White solid (45 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 7.79 – 7.75 (m, 1H), 7.75 – 7.72
(m, 1H), 7.55 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 5.63 (s,
2H), 3.30 – 3.21 (m, 1H), 2.00 – 1.90 (m, 1H), 1.88 – 1.76 (m, 1H), 1.49 (d, J = 6.9 Hz, 3H),
1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.0, 151.7, 144.7, 140.0, 137.9,
129.0, 126.8, 124.8, 123.1, 120.3, 41.0, 30.9, 21.0, 11.9. MS (ESI) calculated for
C14H15N3S, m/z 257.10, found 258.10 (M+H)+.
8o: (S)-2-(2-methylbutyl)thiazolo[4,5-c]quinolin-4-amine
White solid (46 mg, 77%). 1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.5 Hz, 1H),
7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1,
1.1 Hz, 1H), 5.66 (s, 2H), 3.14 (dd, J = 14.6, 6.2 Hz, 1H), 2.96 (dd, J = 14.6, 8.1 Hz, 1H),
2.08 – 1.97 (m, 1H), 1.57 – 1.47 (m, 1H), 1.38 – 1.28 (m, 1H), 1.02 (d, J = 6.7 Hz, 3H), 0.97
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.5, 151.7, 144.7, 140.6, 138.1, 129.0,
126.8, 124.8, 123.1, 120.2, 41.2, 36.3, 29.3, 19.2, 11.5. MS (ESI) calculated for C15H17N3S,
m/z 271.11, found 272.11 (M+H)+.
8p: 2-(3,3,3-trifluoropropyl)thiazolo[4,5-c]quinolin-4-amine
White solid (70 mg, 78%). 1H NMR (500 MHz, CDCl3) δ 7.80 – 7.76 (m, 1H), 7.73 (dd, J =
8.0, 1.0 Hz, 1H), 7.58 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.35 – 7.30 (m, 1H), 5.63 (s, 2H), 3.45
– 3.39 (m, 2H), 2.87 – 2.76 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 166.5, 151.6, 145.0,
140.8, 137.9, 129.4, 126.9, 126.4 (q, 1JCF = 276.5 Hz), 124.9, 123.4, 119.9, 33.1 (q, 2JCF =
29.8 Hz), 26.8 (q, 3JCF = 3.4 Hz). MS (ESI) calculated for C13H10F3N3S, m/z 297.05, found
298.05 (M+H)+.
8q: 2-(4,4,4-trifluorobutyl)thiazolo[4,5-c]quinolin-4-amine
White solid (50 mg, 72%). 1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 0.4 Hz, 1H),
7.73 (dd, J = 8.0, 1.1 Hz, 1H), 7.57 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.32 (ddd, J = 8.1, 7.1,
1.1 Hz, 1H), 5.62 (s, 2H), 3.25 (t, J = 7.2 Hz, 2H), 2.36 – 2.26 (m, 2H), 2.26 – 2.18 (m,
2H). 13C NMR (126 MHz, CDCl3) δ 168.8, 151.6, 144.9, 140.6, 138.1, 129.3, 127.0 (q, 1JCF
= 276.4 Hz), 126.9, 124.9, 123.3, 120.0, 33.1 (q, 2JCF = 29.7 Hz), 32.7, 21.9 (q, 3JCF = 3.0
Hz). MS (ESI) calculated for C14H12F3N3S, m/z 311.07, found 312.07 (M+H)+.
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Synthesis of compound 9: 8-nitro-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 8c (200 mg, 0.82 mmol) in H2SO4 (0.5 mL), was added
HNO3 (0.5 mL) and the reaction mixture was stirred at room temperature for 1 h. The
reaction mixture was neutralized with 1N NaOH and extracted with EtOAc (3 × 15 mL).
The combined organic layer was dried over Na2SO4, concentrated under reduced pressure,
and the crude residue was purified using silica gel column chromatography (5% MeOH/
CH2Cl2) to obtain compound 9 as yellow solid (171 mg, 72%). 1H NMR (400 MHz, CDCl3)
δ 8.68 (d, J = 2.5 Hz, 1H), 8.35 (dd, J = 9.2, 2.6 Hz, 1H), 7.80 (d, J = 9.2 Hz, 1H), 6.09 (s,
2H), 3.17 (dd, J = 8.7, 6.4 Hz, 2H), 1.97 (dd, J = 15.0, 7.5 Hz, 2H), 1.11 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 173.3, 153.6, 148.3, 142.5, 141.2, 138.7, 127.3, 123.2,
121.5, 119.1, 36.2, 23.3, 13.8. MS (ESI) calculated for C13H12N4O2S, m/z 288.07, found
289.08 (M+H)+.
Synthesis of compound 10: 2-propylthiazolo[4,5-c]quinoline-4,8-diamine
To a stirred solution of compound 9 (200 mg, 0.69 mmol) in methanol (5 mL), were added
zinc dust (453 mg, 6.94 mmol) and ammonium formate (437 mg, 6.94 mmol), and the
reaction mixture stirred at room temperature for 30 min. The reaction mixture was then
filtered through celite, the filtrate concentrated under reduced pressure, and purified over
silica gel column chromatography (10% MeOH/CH2Cl2) to afford compound 10 as a yellow
solid (185 mg, 88%). 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.46 (s, 2H), 7.70 (d, J =
8.9 Hz, 1H), 7.00 (dd, J = 8.9, 2.5 Hz, 1H), 6.87 (d, J = 2.4 Hz, 1H), 3.17 – 3.09 (m, 2H),
1.99 – 1.88 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.1, 170.3,
149.2, 143.9, 142.1, 137.1, 129.5, 121.9, 120.7, 118.7, 107.4, 36.1, 23.2, 13.8. MS (ESI)
calculated for C13H14N4S, m/z 258.09, found 259.10 (M+H)+.
Synthesis of compound 11: 8-azido-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 10 (25 mg, 0.096 mmol) in a 1:1 mixture of acetic acid
and water (2 mL), was added sodium nitrite (20 mg, 0.29 mmol) and the reaction mixture
was stirred at room temperature for 1 h. Sodium azide (18.8 mg, 0.29 mmol) was then added
to the reaction mixture and stirred for additional 1 h. The reaction mixture was neutralized
with 1N NaOH and extracted with EtOAc (3 × 10 mL). The combined organic layer was
dried over Na2SO4, concentrated under reduced pressure, and the crude compound was
purified on silica gel column chromatography (5% MeOH/CH2Cl2) to obtain compound 11
as a brown solid (18 mg, 67%). 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.9 Hz, 1H), 7.31
(d, J = 2.5 Hz, 1H), 7.26 – 7.23 (m, 1H), 5.60 (s, 2H), 3.17 – 3.12 (m, 2H), 2.01 – 1.90 (m,
2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.0, 151.3, 139.5, 138.5,
134.8, 128.4, 121.0, 120.8, 113.5, 36.2, 23.4, 13.8. MS (ESI) calculated for C13H12N6S, m/z
284.08, found 285.09 (M+H)+.
Synthesis of compound 12a: 2-(1-(4-amino-2-propylthiazolo[4,5-c]quinolin-8-yl)-1H-1,2,3-
triazol-4-yl)propan-2-ol
To a stirred solution of compound 11 (12 mg, 0.042 mmol) in THF (1 mL), were added
CuSO4.5H2O (1.3 mg, 0.005 mmol, in 0.5 mL water), sodium ascorbate (2.1 mg, 0.010
mmol, in 0.5 mL water), 2-methylbut-3-yn-2-ol (8.4 μL, 0.084 mmol), and the reaction
mixture stirred at room temperature for 1 h. The reaction mixture was diluted with water and
extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na2SO4,
concentrated under reduced pressure, and the crude residue was purified using silica gel
column chromatography (10% MeOH/CH2Cl2) to obtain compound 11 as a white solid (14
mg, 92%). 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 2.0 Hz, 1H), 7.97 (s, 1H), 7.91 – 7.81
(m, 2H), 5.74 (s, 2H), 3.49 (s, 1H), 3.19 – 3.13 (m, 2H), 1.96 (dd, J = 15.0, 7.5 Hz, 2H), 1.74
(s, 6H), 1.10 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.5, 156.5, 152.2, 144.5,
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140.2, 138.7, 132.0, 128.3, 121.5, 120.3, 117.8, 116.4, 68.9, 36.2, 30.7, 23.4, 13.8. MS (ESI)
calculated for C18H20N6OS, m/z 368.14, found 369.15 (M+H)+.
Compounds 12b-12f were synthesized similarly as compound 12a.
12b: (1-(4-amino-2-propylthiazolo[4,5-c]quinolin-8-yl)-1H-1,2,3-triazol-4-yl)methanol
White solid (15 mg, 83%). 1H NMR (500 MHz, DMSO) δ 8.84 (s, 1H), 8.33 (d, J = 2.5 Hz,
1H), 8.06 (dd, J = 9.0, 2.5 Hz, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.13 (s, 2H), 5.37 (t, J = 5.6 Hz,
1H), 4.64 (d, J = 5.9 Hz, 2H), 3.19 (t, J = 7.5 Hz, 2H), 1.88 (dt, J = 14.8, 7.4 Hz, 2H), 1.04
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.8, 152.7, 149.2, 144.5, 139.1, 138.2,
130.8, 127.3, 121.2, 120.9, 118.9, 115.2, 55.1, 35.2, 22.8, 13.5. MS (ESI) calculated for
C16H16N6OS, m/z 340.11, found 341.11 (M+H)+.
12c: 8-(4-phenyl-1H-1,2,3-triazol-1-yl)-2-propylthiazolo[4,5-c]quinolin-4-amine
Solid (19 mg, 93%). 1H NMR (500 MHz, DMSO) δ 9.44 (s, 1H), 8.36 (d, J = 2.5 Hz, 1H),
8.12 (dd, J = 9.0, 2.5 Hz, 1H), 7.97 (dd, J = 8.2, 1.1 Hz, 2H), 7.80 (d, J = 9.0 Hz, 1H), 7.53
(dd, J = 10.6, 4.8 Hz, 2H), 7.44 – 7.37 (m, 1H), 7.17 (s, 2H), 3.21 (t, J = 7.5 Hz, 2H), 1.90
(dd, J = 14.9, 7.4 Hz, 2H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.8,
152.8, 147.3, 144.7, 139.0, 138.2, 130.6, 130.4, 129.1, 128.3, 127.4, 125.3, 120.9, 119.8,
118.9, 115.3, 35.2, 22.8, 13.5. MS (ESI) calculated for C21H18N6S, m/z 386.13, found
387.14 (M+H)+.
12d: 2-propyl-8-(4-propyl-1H-1,2,3-triazol-1-yl)thiazolo[4,5-c]quinolin-4-amine
Yellow solid (16 mg, 86%). 1H NMR (500 MHz, DMSO) δ 8.72 (s, 1H), 8.28 (d, J = 2.4 Hz,
1H), 8.04 (dd, J = 9.0, 2.5 Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.12 (s, 2H), 3.19 (t, J = 7.5 Hz,
2H), 2.71 (t, J = 7.5 Hz, 2H), 1.89 (dd, J = 14.9, 7.4 Hz, 2H), 1.72 (dd, J = 14.9, 7.4 Hz, 2H),
1.04 (t, J = 7.4 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.8,
152.7, 148.0, 144.4, 139.0, 138.2, 130.9, 127.3, 120.8, 120.3, 118.9, 115.0, 35.2, 27.1, 22.8,
22.1, 13.7, 13.5. MS (ESI) calculated for C18H20N6S, m/z 352.15, found 353.15 (M+H)+.
12e: 8-(4-pentyl-1H-1,2,3-triazol-1-yl)-2-propylthiazolo[4,5-c]quinolin-4-amine
Solid (19 mg, 91%). 1H NMR (500 MHz, DMSO) δ 8.71 (s, 1H), 8.27 (d, J = 2.5 Hz, 1H),
8.04 (dd, J = 9.0, 2.5 Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.12 (s, 2H), 3.19 (t, J = 7.5 Hz, 2H),
2.72 (t, J = 7.6 Hz, 2H), 1.89 (dd, J = 14.9, 7.4 Hz, 2H), 1.69 (dt, J = 15.3, 7.6 Hz, 2H), 1.42
– 1.26 (m, 6H), 1.04 (t, J = 7.4 Hz, 3H), 0.87 (dd, J = 9.2, 4.9 Hz, 3H). 13C NMR (126 MHz,
DMSO) δ 171.8, 152.7, 148.2, 144.4, 139.0, 138.2, 130.9, 127.3, 120.8, 120.2, 118.9, 114.9,
35.2, 31.1, 28.8, 28.3, 25.1, 22.8, 22.1, 14.0, 13.5. MS (ESI) calculated for C21H26N6S, m/z
394.19, found 395.20 (M+H)+.
12f: 2-propyl-8-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)thiazolo[4,5-c]quinolin-4-amine
White solid (18 mg, 90%). 1H NMR (500 MHz, DMSO) δ 8.98 (s, 1H), 8.31 (d, J = 2.4 Hz,
1H), 8.07 (dd, J = 9.0, 2.5 Hz, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.13 (s, 2H), 3.19 (t, J = 7.5 Hz,
2H), 1.89 (dd, J = 14.8, 7.4 Hz, 2H), 1.04 (t, J = 7.4 Hz, 3H), 0.36 – 0.33 (m, 9H). 13C NMR
(126 MHz, DMSO) δ 171.8, 152.7, 146.1, 144.4, 139.1, 138.2, 130.7, 128.9, 127.3, 121.3,
118.9, 115.3, 35.2, 22.8, 13.5, −0.9. MS (ESI) calculated for C18H22N6SSi, m/z 382.14,
found 383.14 (M+H)+.
Synthesis of compound 12g: 2-propyl-8-(1H-1,2,3-triazol-1-yl)thiazolo[4,5-c]quinolin-4-
amine
To a stirred solution of compound 12f (20 mg, 0.0.52 mmol) in THF (1 mL) was added
TBAF (20 mg, 0.078 mmol), and the reaction mixture was stirred at room temperature for
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10 h. The reaction mixture was then diluted with water and extracted with EtOAc (3 × 10
mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure, and
the crude material purified using silica gel column chromatography (5% MeOH/CH2Cl2) to
obtain compound 12g as a white solid (14 mg, 87%). 1H NMR (500 MHz, DMSO) δ 8.94
(d, J = 1.1 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.04 (dd, J = 9.0, 2.5 Hz, 1H), 7.98 (d, J = 1.1
Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.12 (s, 2H), 3.17 (t, J = 7.5 Hz, 2H), 1.91 – 1.83 (m, 2H),
1.02 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.7, 152.8, 144.6, 139.1, 138.2,
134.4, 130.7, 127.4, 123.4, 121.2, 118.9, 115.5, 35.23 22.8, 13.5. MS (ESI) calculated for
C15H14N6S, m/z 310.10, found 311.10 (M+H)+.
Synthesis of compound 13a: N8-hexyl-2-propylthiazolo[4,5-c]quinoline-4,8-diamine
To a stirred solution of compound 10 (25 mg, 0.096 mmol) in DMF (2 mL) were added 1-
iodohexane (20.5 mg, 0.096mmol) and potassium carbonate (26.7mg, 0.19 mmol), and the
reaction mixture stirred at room temperature for 4 h. The reaction mixture was diluted with
water and extracted with EtOAc (3 × 10 mL). The organic layer was dried over Na2SO4,
concentrated under reduced pressure, and the crude compound was purified using silica gel
column chromatography (5% MeOH/CH2Cl2) to obtain 13a as a solid (16 mg, 61%). 1H
NMR (500 MHz, CDCl3) δ 7.69 (d, J = 8.9 Hz, 1H), 6.96 (dd, J = 8.9, 2.6 Hz, 1H), 6.67 (d,
J = 2.5 Hz, 1H), 6.15 (s, 2H), 3.87 (s, 1H), 3.18 (t, J = 7.1 Hz, 2H), 3.15 – 3.11 (m, 2H), 1.99
– 1.89 (m, 2H), 1.68 (dt, J = 14.7, 7.2 Hz, 2H), 1.49 – 1.41 (m, 2H), 1.35 (td, J = 7.2, 3.7 Hz,
4H), 1.09 (t, J = 7.4 Hz, 3H), 0.92 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.1,
148.2, 145.5, 141.2, 137.4, 124.8, 120.3, 119.8, 102.9, 44.3, 36.2, 31.8, 29.4, 27.0, 23.3,
22.8, 14.2, 13.8. MS (ESI) calculated for C19H26N4S, m/z 342.19, found 343.20 (M+H)+.
Synthesis of compound 13b: N-(4-amino-2-propylthiazolo[4,5-c]quinolin-8-yl)butyramide
To a stirred solution of compound 10 (20 mg, 0.077 mmol) in CH2Cl2 (2 mL) were added
triethylamine (30 μL, 0.164 mmol) and butyryl chloride (8.7 μL, 0.082); the reaction
mixture was stirred at room temperature for 1 h. The reaction mixture was then diluted with
water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over
Na2SO4, concentrated under reduced pressure, and the crude compound was purified using
silica gel column chromatography (10% MeOH/CH2Cl2) to furnish compound 13b as a
white solid (22 mg, 87%). 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 2.2 Hz, 1H), 7.71 (d, J
= 8.9 Hz, 1H), 7.37 (dd, J = 8.9, 2.4 Hz, 2H), 5.67 (d, J = 1.2 Hz, 2H), 3.13 (t, J = 7.4 Hz,
2H), 2.41 (t, J = 7.4 Hz, 2H), 1.94 (dd, J = 15.0, 7.5 Hz, 2H), 1.85 – 1.74 (m, 2H), 1.11 –
1.02 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 172.0, 171.5, 150.9, 140.6, 138.2, 133.4,
126.8, 122.1, 120.2, 114.6, 39.8, 36.2, 23.3, 19.2, 13.9, 13.8. MS (ESI) calculated for
C17H20N4OS, m/z 328.14, found 329.15 (M+H)+.
Synthesis of compound 14: 8-bromo-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 8c (50 mg, 0.205 mmol) in CH3CN (1 mL) were added
N-bromosuccinimide (44 mg, 0.246 mmol), ammonium acetate (1.6 mg, 0.02 mmol) and the
reaction mixture stirred at room temperature for 12 h. The reaction mixture was then diluted
with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried
over Na2SO4, concentrated under reduced pressure, and the crude material was purified
using silica gel column chromatography (5% MeOH/CH2Cl2) to obtain compound 14 as a
white solid (40 mg, 67%). 1H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 2.0, 0.6 Hz, 1H),
7.61 (dd, J = 3.9, 1.3 Hz, 2H), 5.68 (s, 2H), 3.16 – 3.11 (m, 2H), 1.95 (dt, J = 15.0, 7.4 Hz,
2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.1, 151.8, 143.4, 139.3,
138.4, 132.1, 128.4, 126.9, 121.5, 115.9, 36.2, 2 3 .4, 13.8. MS (ESI) calculated for
C13H12BrN3S, m/z 320.99, found 322.00 (M+H)+.
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Synthesis of compound 15a: N-butyl-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 8c (50 mg, 0.205 mmol) in THF (1 mL) were added
sodium hydride (10 mg, 0.41 mmol) and 1-iodobutane (35 μL, 0.308 mmol), the resulting
mixture was stirred at room temperature for 6 h. The reaction mixture was then diluted with
water and extracted with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4,
concentrated under reduced pressure, and the crude compound was purified using silica gel
column chromatography (5% MeOH/CH2Cl2) to obtain compound 15a (45 mg, 70%). 1H
NMR (500 MHz, CDCl3) δ 7.81 (dd, J = 8.3, 0.5 Hz, 1H), 7.70 – 7.66 (m, 1H), 7.51 (ddd, J
= 8.4, 7.1, 1.5 Hz, 1H), 7.23 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H), 5.96 (t, J = 4.8 Hz, 1H), 3.77 –
3.69 (m, 2H), 3.15 – 3.08 (m, 2H), 1.99 – 1.89 (m, 2H), 1.75 (ddd, J = 14.9, 11.1, 7.5 Hz,
2H), 1.52 (dq, J = 14.7, 7.4 Hz, 2H), 1.08 (t, J = 7.4 Hz, 3H), 1.00 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 170.7, 151.2, 145.3, 138.9, 138.3, 128.6, 126.9, 124.5, 122.1,
119.3, 40.6, 36.0, 31.9, 23.3, 20.3, 14.0, 13.7. MS (ESI) calculated for C17H21N3S, m/z
299.15, found 300.14 (M+H)+.
Compound 15b-c was synthesized similarly as compound 15a.
15b: N-hexyl-2-propylthiazolo[4,5-c]quinolin-4-amine
White solid (9.9 mg, 72%, based on starting material recovery). 1H NMR (400 MHz,
CDCl3) δ 7.81 (d, J = 8.3 Hz, 1H), 7.68 (dd, J = 7.9, 1.1 Hz, 1H), 7.51 (ddd, J = 8.5, 7.1, 1.5
Hz, 1H), 7.23 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 5.96 (t, J = 4.6 Hz, 1H), 3.71 (dt, J = 7.2, 5.8
Hz, 2H), 3.11 (dd, J = 8.7, 6.5 Hz, 2H), 1.94 (dd, J = 15.0, 7.5 Hz, 2H), 1.76 (t, J = 7.3 Hz,
2H), 1.53 – 1.44 (m, 2H), 1.36 (ddd, J = 6.9, 6.2, 3.3 Hz, 4H), 1.08 (t, J = 7.4 Hz, 3H), 0.91
(dd, J = 9.1, 5.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.9, 151.3, 145.5, 139.1, 138.5,
128.8, 127.1, 124.6, 122.3, 119.5, 41.1, 36.2, 31.8, 29.9, 27.1, 23.5, 22.8, 14.2, 13.8. MS
(ESI) calculated for C19H25N3S, m/z 327.18, found 328.18 (M+H)+.
15c: N-hexadecyl-2-propylthiazolo[4,5-c]quinolin-4-amine
White solid (26 mg, 68%). 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 7.9 Hz, 1H), 7.68 (dd,
J = 7.9, 1.1 Hz, 1H), 7.51 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.23 (td, J = 7.1, 3.6 Hz, 1H), 5.96
(s, 1H), 3.71 (dd, J = 12.9, 7.1 Hz, 2H), 3.11 (dd, J = 8.7, 6.5 Hz, 2H), 1.98 – 1.88 (m, 2H),
1.76 (dt, J = 14.8, 7.4 Hz, 2H), 1.51 – 1.43 (m, 2H), 1.30 – 1.21 (m, 24H), 1.08 (t, J = 7.4
Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.9, 151.4, 145.5,
139.1, 138.5, 128.7, 127.1, 124.6, 122.3, 119.5, 41.1, 36.8, 36.1, 32.1, 29.9, 29.8, 29.8, 29.8,
29.8, 29.8, 29.7, 29.6, 29.5, 27.3, 24.8, 23.5, 22.8, 14.3, 13.9. MS (ESI) calculated for
C29H45N3S, m/z 467.33, found 468.35 (M+H)+.
Synthesis of compound 15d: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)formamide
To a stirred solution of compound 8c (50 mg, 0.205 mmol) in 1,4-dioxane (1 mL) were
added 2,2,2-trifluoroethylformate (60 μL, 0.616 mmol) and triethylamine (86 μL, 0.616
mmol). The resulting mixture was stirred at 80 °C for 12 h. The reaction mixture was then
diluted with water and extracted with CH2Cl2 (3 × 10 mL). The combined organic layer was
dried over Na2SO4, concentrated under reduced pressure, and the crude compound was
purified using silica gel column chromatography (3% MeOH/CH2Cl2) to furnish compound
15c as a white solid (26 mg, 46%). 1H NMR (500 MHz, CDCl3) δ 9.84 (d, J = 10.8 Hz, 1H),
8.86 (d, J = 10.3 Hz, 1H), 8.03 – 7.94 (m, 1H), 7.84 (ddd, J = 8.0, 1.4, 0.5 Hz, 1H), 7.67
(ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 7.50 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 3.24 – 3.08 (m, 2H), 2.05
– 1.87 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.7, 162.0, 143.8,
143.2, 141.7, 137.5, 129.5, 128.8, 125.8, 124.8, 121.9, 36.2, 23.1, 13.8. MS (ESI) calculated
for C14H13N3OS, m/z 271.08, found 272.09 (M+H)+.
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Synthesis of compound 15e: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)acetamide
To a stirred solution of compound 8c (20 mg, 0.082 mmol) in pyridine (1 mL) was added
acetyl chloride (5.8 μL, 0.082 mmol), the resulting mixture was stirred at room temperature
for 1 h. The solvent was evaporated under reduced pressure and extracted with CH2Cl2 (3 ×
10 mL). The combined organic layer was dried over Na2SO4, concentrated under reduced
pressure, and the crude compound was purified using silica gel column chromatography (5%
MeOH/CH2Cl2) to furnish compound 15d as a white solid (18 mg, 78%). 1H NMR (500
MHz, CDCl3) δ 8.03 (d, J = 8.3 Hz, 1H), 7.88 (dd, J = 8.1, 0.9 Hz, 1H), 7.72 (ddd, J = 8.4,
7.2, 1.3 Hz, 1H), 7.59 – 7.54 (m, 1H), 3.17 (td, J = 7.6, 2.3 Hz, 2H), 2.77 (s, 3H), 1.96 (dd, J
= 15.0, 7.5 Hz, 2H), 1.09 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.0, 144.7,
138.3, 131.6, 130.0, 127.2, 126.5, 125.9, 125.3, 125.0, 121.2, 36.2, 25.7, 23.2, 13.8. MS
(ESI) calculated for C15H15N3OS, m/z 285.09, found 286.11 (M+H)+.
Compounds 15f-15i were synthesized similarly as compound 15e.
15f: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)butyramide
White solid (20 mg, 78%). 1H NMR (500 MHz, CDCl3) δ 8.96 (s, 1H), 8.04 (d, J = 8.3 Hz,
1H), 7.82 (dd, J = 8.0, 1.0 Hz, 1H), 7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 8.1,
7.1, 1.1 Hz, 1H), 3.21 – 3.04 (m, 4H), 2.01 – 1.92 (m, 2H), 1.92 – 1.82 (m, 2H), 1.10 (td, J =
7.4, 6.1 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 172.1, 144.5, 143.5, 140.8, 138.6, 129.2,
129.2, 125.7, 124.6, 121.4, 39.9, 36.2, 23.2, 18.6, 14.1, 13.8. MS (ESI) calculated for
C17H19N3OS, m/z 313.12, found 314.13 (M+H)+.
15g: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)octanamide
White solid (25 mg, 83%). 1H NMR (400 MHz, CDCl3) δ 8.95 (s, 1H), 8.04 (d, J = 8.3 Hz,
1H), 7.82 (dd, J = 8.0, 0.9 Hz, 1H), 7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.52 – 7.44 (m, 1H),
3.15 (t, J = 7.5 Hz, 4H), 1.96 (dd, J = 14.9, 7.4 Hz, 2H), 1.83 (dd, J = 15.2, 7.7 Hz, 2H), 1.54
– 1.45 (m, 2H), 1.39 – 1.23 (m, 6H), 1.09 (t, J = 7.4 Hz, 3H), 0.89 (t, J = 6.9 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 172.1, 144.5, 143.5, 140.8, 138.6, 129.3, 129.2, 125.7, 124.7,
121.4, 38.1, 36.2, 31.9, 29.8, 29.6, 29.3, 25.2, 23.2, 22.8, 14.2, 13.8. MS (ESI) calculated for
C21H27N3OS, m/z 369.19, found 370.22 (M+H)+.
15h: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)palmitamide
Yellow solid (33 mg, 84%). 1H NMR (500 MHz, CDCl3) δ 8.95 (s, 1H), 8.04 (d, J = 8.3 Hz,
1H), 7.83 (dd, J = 8.0, 1.0 Hz, 1H), 7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 10.4,
5.8, 2.2 Hz, 1H), 3.20 – 3.10 (m, 4H), 2.01 – 1.91 (m, 2H), 1.84 (dt, J = 15.2, 7.6 Hz, 2H),
1.53 – 1.44 (m, 2H), 1.43 – 1.34 (m, 2H), 1.34 – 1.19 (m, 20H), 1.09 (t, J = 7.4 Hz, 3H),
0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.1, 144.5, 143.6, 140.8, 138.6,
129.3, 129.2, 125.7, 124.7, 121.5, 38.1, 36.2, 32.1, 29.8, 29.8, 29.8, 29.7, 29.6, 29.6, 29.5,
25.2, 23.2, 22.8, 14.3, 13.8. MS (ESI) calculated for C29H43N3OS, m/z 481.31, found
482.33 (M+H)+.
15i: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)benzamide
White solid (24 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 8.24 (d, J = 8.5 Hz,
1H), 8.07 (d, J = 7.4 Hz, 2H), 7.86 (d, J = 7.6 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.62 – 7.51
(m, 4H), 3.19 (t, J = 7.6 Hz, 2H), 1.98 (dt, J = 14.9, 7.5 Hz, 2H), 1.12 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 172.4, 164.7, 144.7, 143.8, 140.9, 139.3, 135.0, 132.4,
130.1, 129.2, 129.0, 127.7, 126.1, 124.5, 121.8, 36.2, 23.4, 13.9. MS (ESI) calculated for
C20H17N3OS, m/z 347.11, found 348.12 (M+H)+.
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Synthesis of compound 15j: 2-azido-N-(2-propylthiazolo[4,5-c]quinolin-4-yl)acetamide
To a stirred solution of 2-azidoacetic acid (18.6 mg, 0.123 mmol) in DMF (1 mL) were
added triethylamine (23 μL, 0.164 mmol) and HBTU (46.6 mg, 0.123 mmol), and the
resulting mixture was stirred at room temperature for 15 min. Compound 8c (20 mg, 0.082
mmol) was then added, and stirring continued for 4 h. The reaction mixture was diluted with
water and extracted with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4,
concentrated under reduced pressure, and the crude residue was purified by silica gel
column chromatography (5% MeOH/CH2Cl2) to obtain compound 15j as a white solid (50
mg, 96%). 1H NMR (500 MHz, CDCl3) δ 9.25 (d, J = 0.6 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H),
7.84 (dd, J = 8.0, 1.0 Hz, 1H), 7.68 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.52 (ddd, J = 8.1, 7.2,
1.1 Hz, 1H), 4.86 (s, 2H), 3.17 (t, J = 7.5 Hz, 2H), 2.01 – 1.92 (m, 2H), 1.10 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 172.7, 143.6, 143.1, 141.4, 138.2, 129.5, 129.1, 126.2,
124.8, 121.6, 54.7, 36.2, 23.2, 13.8. MS (ESI) calculated for C15H14N6OS, m/z 326.10,
found 327.11 (M+H)+.
Compounds 15k-15l were synthesized similarly as compound 15j.
15k: 3-azido-N-(2-propylthiazolo[4,5-c]quinolin-4-yl)propanamide
White solid (59 mg, 85%). 1H NMR (500 MHz, CDCl3) δ 9.07 (s, 1H), 8.03 (d, J = 8.3 Hz,
1H), 7.84 (dd, J = 8.0, 0.9 Hz, 1H), 7.67 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.53 – 7.48 (m, 1H),
3.82 (t, J = 6.6 Hz, 2H), 3.59 (s, 2H), 3.16 (t, J = 7.5 Hz, 2H), 2.01 – 1.91 (m, 2H), 1.09 (dd,
J = 9.3, 5.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.4, 144.1, 143.3, 141.1, 138.3,
129.4, 129.1, 125.9, 124.7, 121.5, 46.9, 37.6, 36.2, 23.2, 13.8. MS (ESI) calculated for
C16H16N6OS, m/z 340.11, found 341.12 (M+H)+.
15l: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)pent-4-ynamide
White solid (60 mg, 90%). 1H NMR (500 MHz, CDCl3) δ 9.02 (s, 1H), 8.05 (d, J = 8.3 Hz,
1H), 7.82 (dd, J = 8.0, 0.9 Hz, 1H), 7.66 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 8.1,
7.1, 1.1 Hz, 1H), 3.49 (s, 2H), 3.15 (dd, J = 8.6, 6.5 Hz, 2H), 2.75 (ddd, J = 9.0, 6.9, 2.7 Hz,
2H), 2.03 (t, J = 2.7 Hz, 1H), 2.00 – 1.90 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 172.2, 144.2, 143.4, 141.0, 138.4, 129.3, 129.2, 125.8, 124.7, 121.5, 83.6,
68.9, 37.2, 36.2, 23.2, 14.3, 13.8. MS (ESI) calculated for C18H17N3OS, m/z 323.11, found
324.13 (M+H)+.
Synthesis of compound 15m: methyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate
To a stirred solution of 8c (50 mg, 0.205 mmol) in CH2Cl2 (2 mL) were added triethylamine
(57 μL, 0.410 mmol) and methyl chloroformate (32 μL, 0.3075 mmol), and the resulting
mixture was stirred at room temperature for 5 h. The reaction mixture was diluted with
water and extracted with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4,
concentrated under reduced pressure, and the crude residue was purified by silica gel
column chromatography (5% MeOH/CH2Cl2) to obtain compound 15m (58 mg, 94%) as a
white solid. 1H NMR (500 MHz, CDCl3) δ 8.51 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.82 (dd, J
= 8.0, 0.9 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.52 – 7.46 (m, 1H), 3.91 (s, 3H), 3.17 – 3.11 (m,
2H), 1.95 (dt, J = 14.8, 7.4 Hz, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
172.2, 152.2, 144.3, 143.8, 140.8, 138.6, 129.7, 129.2, 125.7, 124.5, 121.4, 52.9, 36.2, 23.3,
13.8. MS (ESI) calculated for C15H15N3O2S, m/z 301.09, found 302.17 (M+H)+.
Compounds 15n-15p were synthesized similarly as compound 15m.
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Synthesis of compound 15n: ethyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate
Yellow solid (50 mg,77%). 1H NMR (500 MHz, CDCl3) δ 8.48 (s, 1H), 8.17 (t, J = 8.3 Hz,
1H), 8.17 (t, J = 8.3 Hz, 1H), 7.81 (dd, J = 8.0, 1.0 Hz, 1H), 7.81 (dd, J = 8.0, 1.0 Hz, 1H),
7.69 – 7.61 (m, 1H), 7.51 – 7.45 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.18 – 3.12 (m, 2H), 2.01
– 1.90 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 172.1, 151.6, 144.5, 143.8, 140.8, 138.6, 129.8, 129.1, 125.7, 124.5, 121.3, 61.8,
36.2, 23.3, 14.7, 13.8. MS (ESI) calculated for C16H17N3O2S, m/z 315.10, found 316.19 (M
+H)+.
Synthesis of compound 15o: butyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate
White solid (52 mg,74%). 1H NMR (500 MHz, CDCl3) δ 8.47 (s, 1H), 8.18 – 8.13 (m, 1H),
7.81 (dd, J = 8.0, 0.9 Hz, 1H), 7.66 (qd, J = 8.5, 2.6 Hz, 1H), 7.52 – 7.45 (m, 1H), 4.31 (t, J
= 6.7 Hz, 2H), 3.19 – 3.11 (m, 2H), 2.02 – 1.91 (m, 2H), 1.80 – 1.70 (m, 2H), 1.54 – 1.44
(m, 2H), 1.13 – 1.06 (m, 3H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
172.1, 151.8, 144.5, 143.7, 140.8, 138.6, 129.8, 129.1, 125.7, 124.5, 121.3, 65.7, 36.2, 31.0,
23.3, 19.2, 13.9, 13.8. MS (ESI) calculated for C18H21N3O2S, m/z 343.14, found 344.14 (M
+H)+.
Synthesis of compound 15p: octyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate
White solid (60 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 8.47 (s, 1H), 8.17 – 8.13 (m, 1H),
7.81 (dd, J = 8.0, 1.0 Hz, 1H), 7.68 – 7.61 (m, 1H), 7.47 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 4.30
(t, J = 6.7 Hz, 2H), 3.15 (dd, J = 9.7, 5.5 Hz, 2H), 2.02 – 1.90 (m, 3H), 1.80 – 1.71 (m, 2H),
1.51 – 1.39 (m, 3H), 1.38 – 1.22 (m, 10H), 1.09 (dd, J = 9.0, 5.8 Hz, 5H), 0.88 (t, J = 7.0 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 172.1, 151.8, 144.5, 143.9, 140.8, 138.6, 129.7, 129.1,
125.6, 124.5, 121.3, 66.0, 36.2, 31.9, 29.4, 29.4, 29.0, 26.0, 23.3, 22.8, 14.2, 13.8. MS (ESI)
calculated for C22H29N3O2S, m/z 399.20, found 400.21 (M+H)+.
Synthesis of compound 15q: 1-(2-propylthiazolo[4,5-c]quinolin-4-yl)urea
To a stirred solution of 8c (50 mg, 0.205 mmol) in acetonitrile (2 mL) were added NaHCO3
(26 mg, 0.307 mmol) and chlorosulfonyl isocyanate (27 μL, 0.307 mmol), and the resulting
mixture was stirred at room temperature for 1 h. Then, one more equivalent of
chlorosulfonyl isocyanate (27 μL, 0.307 mmol) was added and the reaction mixture was
stirred at room temperature for additional 1h. The reaction mixture was diluted with water
and extracted with EtOAc (3 × 10 mL). The organic layer was dried over Na2SO4,
concentrated under reduced pressure, and the crude residue was purified by silica gel
column chromatography (5% MeOH/CH2Cl2) to obtain compound 15q as a white solid
(26mg, 45% starting material was recovered). 1H NMR (500 MHz, CDCl3) δ 9.84 (d, J =
10.8 Hz, 1H), 8.86 (d, J = 10.3 Hz, 1H), 8.03 – 7.94 (m, 1H), 7.84 (ddd, J = 8.0, 1.4, 0.5 Hz,
1H), 7.67 (ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 7.50 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 3.24 – 3.08 (m,
2H), 2.05 – 1.87 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.7,
162.0, 143.8, 143.2, 141.7, 137.5, 129.5, 128.8, 125.8, 124.8, 121.9, 36.2, 23.1, 13.8. MS
(ESI) calculated for C14H14N4OS, m/z 286.09, found 287.09 (M+H)+.
Synthesis of compound 15r: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)methanesulfonamide
To a stirred solution of 8c (40 mg, 0.146 mmol) in dichloromethane (2 mL) was added
methyl methanesulfonyl chloride (26 μL, 0.292 mmol), and the resulting mixture was stirred
at room temperature for12 h. The reaction mixture was diluted with water and extracted with
CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4, concentrated under reduced
pressure, and the crude residue was purified by silica gel column chromatography (5%
MeOH/CH2Cl2) to obtain compound 15r as a white solid (34 mg, 65%). 1H NMR (500
MHz, CDCl3) δ 11.91 (s, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.40 (t, J =
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7.6 Hz, 2H), 3.29 (s, 3H), 3.20 – 3.15 (m, 2H), 1.97 – 1.87 (m, 2H), 1.07 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 173.0, 148.8, 143.4, 141.6, 133.5, 130.6, 125.4, 125.2,
117.5, 116.9, 43.2, 36.3, 23.7, 13.8. MS (ESI) calculated for C14H15N3O2S2, m/z 321.06,
found 322.06 (M+H)+.
Compounds 15s-15v were synthesized similarly as compound 15r.
Synthesis of compound 15s: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)ethanesulfonamide
White solid (35 mg, 63%). 1H NMR (500 MHz, CDCl3) δ 12.05 (s, 1H), 7.72 (d, J = 6.7 Hz,
1H), 7.58 (t, J = 7.1 Hz, 1H), 7.40 (d, J = 7.3 Hz, 2H), 3.34 (d, J = 5.0 Hz, 2H), 3.18 (t, J =
7.7 Hz, 2H), 1.99 – 1.87 (m, 2H), 1.46 (t, J = 7.4 Hz, 3H), 1.07 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 172.9, 149.9, 143.3, 141.9, 133.5, 130.7, 125.5, 125.0, 117.7,
116.8, 49.4, 36.3, 23.8, 13.8, 8.3. MS (ESI) calculated for C15H17N3O2S2, m/z 335.08,
found 336.08 (M+H)+.
Synthesis of compound 15t: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)propane-1-sulfonamide
White solid (35 mg, 61%). 1H NMR (500 MHz, CDCl3) δ 12.05 (s, 1H), 7.72 (d, J = 6.7 Hz,
1H), 7.58 (t, J = 7.1 Hz, 1H), 7.40 (d, J = 7.3 Hz, 2H), 3.34 (d, J = 5.0 Hz, 2H), 3.18 (t, J =
7.7 Hz, 2H), 1.99 – 1.87 (m, 2H), 1.46 (t, J = 7.4 Hz, 3H), 1.07 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 172.9, 149.9, 143.3, 141.9, 133.5, 130.7, 125.5, 125.0, 117.7,
116.8, 49.4, 36.3, 23.8, 13.8, 8.3. MS (ESI) calculated for C16H19N3O2S2, m/z 349.09,
found 350.09 (M+H)+.
Synthesis of compound 15u: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)butane-1-sulfonamide
White solid (37 mg, 62%). 1H NMR (500 MHz, CDCl3) δ 12.04 (s, 1H), 7.71 (d, J = 6.7 Hz,
1H), 7.57 (t, J = 7.0 Hz, 1H), 7.39 (d, J = 6.2 Hz, 2H), 3.32 (s, 2H), 3.18 (t, J = 7.7 Hz, 2H),
2.00 – 1.82 (m, 4H), 1.55 – 1.40 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H), 0.94 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 172.8, 149.7, 143.3, 141.9, 133.5, 130.7, 125.5, 125.0,
117.6, 116.8, 54.8, 36.3, 25.5, 23.8, 21.7, 13.8, 13.8. MS (ESI) calculated for
C17H21N3O2S2, m/z 363.11, found 364.11 (M+H)+.
Synthesis of compound 15v: 4-methyl-N-(2-propylthiazolo[4,5-c]quinolin-4-
yl)benzenesulfonamide
White solid (40 mg, 61%). 1H NMR (500 MHz, CDCl3) δ 12.04 (s, 1H), 7.71 (d, J = 6.7 Hz,
1H), 7.57 (t, J = 7.0 Hz, 1H), 7.39 (d, J = 6.2 Hz, 2H), 3.32 (s, 2H), 3.18 (t, J = 7.7 Hz, 2H),
2.00 – 1.82 (m, 4H), 1.55 – 1.40 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 172.8, 149.0, 143.4, 143.0, 142.1, 139.9, 133.5, 130.7,
129.4, 126.7, 125.5, 125.1, 117.7, 117.0, 36.2, 23.67, 21.7, 13.8. MS (ESI) calculated for
C20H19N3O2S2, m/z 397.09, found 398.10 (M+H)+.
Synthesis of compound 15w: diethyl (2-propylthiazolo[4,5-c]quinolin-4-
yl)phosphoramidate
To a stirred solution of 8c (50 mg, 0.205 mmol) in CH2Cl2 (2 mL) was added diethyl
chlorophosphate (60 μL, 0.810 mmol), and the resulting mixture was stirred at room
temperature for12 h. The reaction mixture was diluted with water and extracted with CH2Cl2
(3 × 10 mL). The organic layer was dried over Na2SO4, concentrated under reduced
pressure, and the crude residue was purified by silica gel column chromatography (5%
MeOH/CH2Cl2) to obtain compound 15w as a white solid (45 mg, 56%). 1H NMR (500
MHz, DMSO) δ 8.41 (d, J = 10.1 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H),
7.68 (dd, J = 11.2, 4.0 Hz, 1H), 7.49 (t, J = 7.4 Hz, 1H), 4.24 (p, J = 7.2 Hz, 4H), 3.20 (t, J =
7.5 Hz, 2H), 1.94 – 1.85 (m, 2H), 1.27 (t, J = 7.0 Hz, 6H), 1.02 (t, J = 7.4 Hz, 3H). 13C
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NMR (126 MHz, DMSO) δ 171.9, 147.0, 143.0, 140.3, 138.0 (d, J = 10.4 Hz), 131.2, 129.2
(d, J = 207.2 Hz), 127.8 (d, J = 94.8 Hz), 124.9 (d, J = 12.8 Hz),, 120.2, 63.1 (d, J = 5.6 Hz),
35.2, 63.1 (d, J = 5.6 Hz), 16.2 (d, J = 6.8 Hz) 13.5. MS (ESI) calculated for
C17H22N3O3PS, m/z 379.11, found 380.12 (M+H)+.
Synthesis of compound 17: 1-(2-propylthiazolo[4,5-c]quinolin-4-yl)guanidine
Compound 7c (100 mg, 0.411 mmol) was dissolved in POCl3 (3 mL) and stirred at 100 °C
for 1 h. POCl3 was evaporated under reduced pressure, ice cold water was added and the
residue was extracted with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4,
concentrated under reduced pressure to give crude 16 (100 mg, 93%) which was used further
without purification. To a stirred solution of guanidine (62 mg, 0.615 mmol) in 1,4 dioxane
(2 mL) was added NaH (12 mg, 0.492 mmol), the reaction mixtures was stirred at 60 °C for
30 min. Compound 16 (30 mg, 0.123 mmol) in DMF (2 mL) was added and heating was
continued at 90 °C for 12 h. The reaction mixture was diluted with water and extracted with
CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4, concentrated under reduced
pressure, and the crude residue was purified by silica gel column chromatography (10%
MeOH/CH2Cl2) to obtain compound 17 as a yellow solid (25 mg, 71%,).1H NMR (500
MHz, MeOD) δ 8.05 (dd, J = 8.4, 0.5 Hz, 1H), 8.00 – 7.96 (m, 1H), 7.75 (ddd, J = 8.4, 7.1,
1.4 Hz, 1H), 7.62 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 3.25 (dd, J = 8.7, 6.4 Hz, 2H), 2.06 – 1.97
(m, 2H), 1.11 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 175.2, 157.5, 146.0,
143.5, 142.7, 138.9, 131.0, 129.3, 128.0, 125.9, 122.5, 36.9, 24.2, 14.0. MS (ESI) calculated
for C14H15N5S, m/285.10, found 286.11 (M+H)+.
Compounds 18a were synthesized similarly as compound 15c.
Synthesis of compound 18a: N-(2-butylthiazolo[4,5-c]quinolin-4-yl)formamide
White solid (32 mg, 71%).1H NMR (500 MHz, CDCl3) δ 9.85 (d, J = 10.8 Hz, 1H), 8.86 (d,
J = 10.3 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.85 (dd, J = 8.0, 0.9 Hz, 1H), 7.67 (ddd, J = 8.4,
7.1, 1.4 Hz, 1H), 7.50 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.20 – 3.16 (m, 2H), 1.91 (dt, J = 15.2,
7.6 Hz, 2H), 1.55 – 1.45 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
172.8, 161.9, 143.7, 143.2, 141.6, 137.4, 129.4, 128.7, 125.7, 124.7, 121.8, 33.8, 31.6, 22.2,
13.8. MS (ESI) calculated for C15H15N3OS, m/z 285.09, found 286.10 (M+H)+.
Compounds 18b-c were synthesized similarly as compound 15d.
Synthesis of compound 18b: N-(2-butylthiazolo[4,5-c]quinolin-4-yl)acetamide
White solid (50 mg, 85%). 1H NMR (500 MHz, CDCl3) δ 8.97 (s, 1H), 8.02 (d, J = 8.3 Hz,
1H), 7.82 (ddd, J = 8.0, 1.4, 0.5 Hz, 1H), 7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J =
8.1, 7.1, 1.2 Hz, 1H), 3.21 – 3.13 (m, 2H), 2.82 (s, 3H), 1.96 – 1.85 (m, 2H), 1.55 – 1.44 (m,
2H), 1.04 – 0.96 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 172.4, 144.4, 143.4, 140.9, 138.5,
129.2, 129.1, 125.7, 124.7, 121.5, 34.0, 31.8, 25.9, 22.3, 13.9. MS (ESI) calculated for
C16H17N3OS, m/z 299.11, found 300.11 (M+H)+.
Synthesis of compound 18c: N-(2-butylthiazolo[4,5-c]quinolin-4-yl)butyramide
White solid (55 mg, 87%). 1H NMR (500 MHz, CDCl3) δ 8.95 (s, 1H), 8.05 (d, J = 8.3 Hz,
1H), 7.82 (ddd, J = 8.0, 1.4, 0.4 Hz, 1H), 7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J =
8.1, 7.1, 1.2 Hz, 1H), 3.22 – 3.06 (m, 4H), 1.95 – 1.83 (m, 4H), 1.54 – 1.45 (m, 2H), 1.10 (t,
J = 7.4 Hz, 3H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.2, 144.3,
143.4, 140.7, 138.4, 129.1, 129.0, 125.6, 124.5, 121.3, 39.8, 33.8, 31.7, 22.2, 18.5, 14.0,
13.8. MS (ESI) calculated for C18H21N3OS, m/327.14, found 328.14 (M+H)+.
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Human TLR-7/-8 Reporter Gene assays (NF-κB induction)
The induction of NF-κB was quantified using HEK-Blue-7 (hTLR7-specific) and HEK-
Blue-8 (hTLR8-specific) cells as previously described by us.27,32,33 HEK293 cells stably co-
transfected with human TLR7 or human TLR8 and secreted alkaline phosphatase (sAP),
were maintained in HEK-Blue™ Selection medium containing zeocin and normocin. Stable
expression of secreted alkaline phosphatase (sAP) under control of NF-κB/AP-1 promoters
is inducible by appropriate TLR agonists, and extracellular sAP in the supernatant is
proportional to NF-κB induction. HEK-Blue cells were incubated at a density of ~105 cells/
ml in a volume of 80 μl/well, in 384-well, flat-bottomed, cell culture-treated microtiter
plates until confluency was achieved, and subsequently stimulated with graded
concentrations of stimuli. sAP was assayed spectrophotometrically using an alkaline
phosphatase-specific chromogen (present in HEK-detection medium as supplied by the
vendor) at 620 nm.
Immunoassays for Interferon (IFN)-α, IFN-γ, Interleukin (IL)-12, IL-18, and cytokines
Fresh human peripheral blood mononuclear cells (hPBMC) were isolated from human blood
obtained by venipuncture with informed consent and as per institutional guidelines on
Ficoll-Hypaque gradients as described elsewhere.62 Aliquots of PBMCs (105 cells in 100
μL/well) were stimulated for 12 h with graded concentrations of test compounds.
Supernatants were isolated by centrifugation, and were assayed in triplicates using either
high-sensitivity analyte-specific ELISA kits (PBL Interferon Source, Piscataway, NJ and
R&D Systems, Inc., Minneapolis, MN), or analyte-specific multiplexed cytokine/chemokine
bead array assays as reported by us previously.63
Rabbit immunization and antigen-specific ELISA
All experiments were performed at Harlan Laboratories (Indianapolis, IN) in accordance
with institutional guidelines (University of Kansas IACUC permit # 119-06). Cohorts of
adult female New Zealand White rabbits (n = 3 per cohort) were immunized intramuscularly
in the flank region with (a) 100 μg of bovine α-lactalbumin in 0.2 mL saline, or (b) 100 μg
of bovine α-lactalbumin plus 100 μg of either 8c or 8d in 0.2 mL saline. Pre-immune test-
bleeds were first obtained on Day 1 via venipuncture of the marginal vein of the ear.
Animals were immunized on Days 1 and 15. A final test-bleed was performed via the
marginal vein of the ear on Day 28. Sera were stored at – 80 °C until used. Bovine α-
lactalbumin-specific ELISAs were performed in 384-well format using automated liquid
handling methods as described by us.35
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TLR8 and TLR7 agonistic potencies of the C2-alkyl thiazoloquinoline homologues. Data
points represent means and standard deviations of EC50 values derived from dose-response
profiles and are computed on quadruplicates.
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TLR8- and TLR7-specific NF-κB induction profiles of branched-chain and trifluoromethyl
analogues of 8c and 8d. Means and SD obtained from quadruplicate samples are shown.
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EC50 values of proinflammatory cytokine induction in human PBMCs by analogues of 8c
and 8d. Representative data from three independent experiments are shown.
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TLR8 induction by C4-amides of 8c (Panel A) and 8d (Panel B). Data points represent
means and standard deviations on quadruplicates.
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Dose-response profiles of proinflammatory cytokine induction in hPBMCs by C4-amides of
8c (Panel A) and 8d (Panel B). Representative data from three independent experiments are
presented. Vehicle controls (not shown) elicited undetectable levels of cytokines.
Kokatla et al. Page 32














Box-plots of anti-bovine α-lactalbumin IgG titers in cohorts of three rabbits immunized with
α-lactalbumin adjuvanted with either 8c or 8d. Means and medians of titers are represented
by □ and — symbols within the box, respectively, and the X symbols indicate the 1% and
99% percentile values.
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Syntheses of C2-alkylthiazoloquinoline analogues. Reagents: (i) HCl, HON=CHCH2NO2,
H2O; (ii) (CH3CO)2O, CH3COOK; (iii) Pt/C, H2, DMF; (iv) RCOCl, Et3N, CH2Cl2:
DMF(10:1); (v) P2S5, pyridine; (vi) m-CPBA, CHCl3; (vii) (a) benzoyl isocyanate, CH2Cl2,
(b) NaOCH3, MeOH.
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Modification at the C8 position. Reagents: (i) HNO3, H2SO4; (ii) Zn, NH4COOH, MeOH;
(iii) NaNO2, CH3COOH, NaN3; (iv) alkyne, CuSO4, sodium ascorbate, THF, H2O (v)
TBAF, THF.
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Synthesis of C8 N-alkyl and N-acyl analogues. Reagents: (i) For 13a, C6H13I, K2CO3,
DMF; For 13b, C3H7COCl, Et3N, CH2Cl2.
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Synthesis of 8-bromothiazoloquinoline. Reagents: (i) NBS, NH4OAc, CH3CN.
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Syntheses of C4 N-alkyl and N-acyl analogues. Reagents: (i) For 15a 15b and 15c, RX,
NaH, THF; For 15d, 2,2,2-trifluoroethylformate, Et3N; For 15e-i, RCOCl, Py; For 15j-l,
RCO2H, HBTU, Et3N; For 15m-p, ROCOCl, Et3N, CH2Cl2; For 15q, ClSO2NCO,
NaHCO3; For 15r-v, RSO2Cl, CH2Cl2; For 15w, ClP(O)OEt2, CH2Cl2.
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Syntheses of C4 guanidino analog. Reagents: (i) POCl3, 100 °C; (ii) guanidine
hydrochloride, NaH, 1,4-dioxane.
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Syntheses of C4 N-alkyl and N-acyl analogues of 8d. Reagents: (i) 2,2,2-
trifluoroethylformate, Et3N; For 18a; RCOCl, pyridine for 18b and 18c.
Kokatla et al. Page 40

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Org Biomol Chem. Author manuscript; available in PMC 2014 February 21.
